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MODULAR SYNTHESIS AND HYDROALKYLATION OF VICINALLY FUNCTIONALIZED 




The stereocontrolled synthesis of functionalized piperazines is of great interest to 
pharmaceutical companies owing to their multiple biological activities such as antidepressant, 
antiparasitic, anticancer and antiretroviral. Current methods towards functionalized piperazines 
include intramolecular cyclization of appropriately tethered on acyclic precursors as well as α-C–
H functionalization of intact piperazine rings. Although effective for the most part, these 
methods suffer from drawbacks such as the use of expensive catalysts, potentially toxic reagents, 
limited scope and functional group compatibility. Seeking to side-step some of the 
aforementioned limitations, we herein describe a step-economical-, cost-effective-, transition 
metal-free-,  and mild approach to highly functionalized piperazines, including [3.3.1]-bicyclic 
piperazines. The success of a novel enolate hydroalkylation methodology hinges on a cascade 
reaction triggered by the addition of allyl magnesium bromide to a vicinally functionalized 
piperazinonate. Furthermore, we have successfully synthesized fluorinated ketopiperazine, in 
hopes of potentially modulating biological properties such as pharmacokinetic and 
physicochemical properties. The [3.3.1] azabicyclic piperazinols and fluorine-containing 2-
oxopiperazines are subsequently engaged in structure-activity-relationship (SAR) studies on 
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CHAPTER 1: INTRODUCTION 
1.1 Relevance of N-Heterocycles 
Heterocyclic compounds are carbon-based molecules that contain at least one different 
atom within the ring. A renowned class of heterocycles are nitrogen-containing heterocycles 
commonly referred to as N-heterocycles or azaheterocycles. There is a great range of diversity of 
N-heterocycles that can be easily accessed. For example, the ring size of azaheterocycles can 
vary from the minimum of 3 atoms to macrocyclic structures with >11 atoms. Other properties 
include molecular geometry, rigidity, and aromaticity. However, all these subtle differences do 
not hinder the ability for possible bioactivity and presence in Food and Drug Administration 
(FDA)-approved pharmaceuticals. Ring structures in general are important building blocks in 
pharmaceuticals. A survey of the most common rings found in pharmaceuticals revealed that 33 
of the top 50 are nitrogen containing heterocycles.1 There are distinguishable features between 
these azaheterocycles, including aromaticity, bicyclic structures, and inclusion of multiple 
heteroatoms. It is important to note that 5- and 6-membered azaheterocycles dominate in this 
context. 
As of 2014, 59% of small-molecule FDA-approved drugs contain an azaheterocycle.2 
Aside from small-molecule/synthetic drugs, azaheterocycles are found in bioactive compounds 
isolated from plants, fungi, and animals. Drug classification of azaheterocycles is greatly diverse. 
Some sub-classes include antihistamines, anesthetics, antidepressants, and antibiotics. 
Additionally, many have shown promising activity in antiparkinson, anticancer, and 
antiretroviral treatments. The abundance of N-heterocycles and their potent bioactivity has 
intrigued both medicinal and synthetic chemists. Particularly, a main interest and challenge for 




As seen in Figure 1-1, one of these azaheterocycles is the piperazine motif which is 
currently the third most common azaheterocycle found in FDA-approved pharmaceuticals.2 
Aside from its prevalence in drugs, piperazines are also found in plastics, fragrances, ligands, 
pesticides and brake fluid. Additionally, amine blends containing piperazine and 
methyldiethanolamine (MDEA) are used for the sweetening of crude oil through the removal of 
carbon dioxide and hydrogen sulfide.3,4 Piperazine rings are known for increasing binding 
affinity, hydrophilicity, and solubility as well as for their hydrogen bonding abilities.5 In this 
research, we seek to explore synthetic application towards functionalized piperazines and post-
diversification of the scaffold. 
 





 1.1.1 Relevance of Piperazines 
As stated in the preceding section, the piperazine scaffold is the third most abundant N-
heterocycle in FDA-approved drugs. Although the third position is impressive, this placement 
may be attributed to the synthetic challenges that the piperazine entity poses in contrast to the 
two azaheterocycles before it. As more efficient syntheses are developed, there is a possibility 
that the piperazine motif will rank higher. This idea is supported by the status of the piperazine 
ring as a privileged scaffold owing to its multiple biological activities. Examples of piperazines 
in pharmaceuticals are illustrated in Figure 1-2. 
 
Figure 1-2 Examples of piperazine containing FDA approved drugs 
Aripiprazole (Abilify®) is an atypical third generation antipsychotic (TGA) that is 
currently used for the treatment of schizophrenia, bipolar I disorder and irritability associated 
with both Tourette’s syndrome and autism spectrum disorder.6 Likewise, it is used as an 
accompanying drug in the treatment of major depression disorder (MDD).7 Aripiprazole is a 
unique antipsychotic since it acts as a partial agonist of the D2 dopamine auto-receptor. This 
TGA distinguishable traits are its low extra pyramidal side effects and low weight gain, which 
are common in first generation antipsychotics (FGA) and second generation antipsychotic 
(SGA), respectively. The approval of aripiprazole motivated antipsychotic drug discovery to lean 
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towards an agonist-based form rather than antagonist-based form. Aripiprazole has a piperazine 
scaffold with two substituents on the nitrogen atoms. On one nitrogen atom, there is an aryl 
group and on the other nitrogen is a tethered δ-lactam motif. Sildenafil (Viagra®) acts as a 
phosphodiesterase type 5 (PDE5) inhibitor to treat erectile dysfunction.8 It blocks degradation of 
cyclic guanosine monophosphate (cGMP) by PDE5 to allow vasodilation and increase blood 
flow. Apart from its medical use, sildenafil is a great example of drug discovery through clinical 
observations. It was initially developed to treat angina but was found to have no clinical effect on 
blood flow of this desired location.9 An interesting side effect was the increase of erectile 
function. It was ultimately concluded that corporal erectile tissue was abundant in PDE5. 
Sildenafil only has substituents on the nitrogen with one being a methyl group and the other a 
sulfonyl group. Dasatinib (Sprycel®) is a highly effective anticancer pharmaceutical that is used 
to treat chronic myelogenous leukemia and Philadelphia-positive acute lymphoblastic leukemia 
(Ph+ ALL).10 Dasatinib is classified as a second-generation BCR-ABL tyrosine kinase inhibitor 
and has the distinction of being a dual SRC/ABL kinase inhibitor.11 This is highly valuable as 
activation of SRC can cause brain, breast, colon, lung, and pancreatic cancer. It has demonstrated 
greater potency than nilotinib, another second generation BCR-ABL kinase inhibitor, by 16-
fold.12 There are three azaheterocycles present in the structure, which are a piperazine, thiazole 
and pyrimidine. Congruent with aripiprazole and sildenafil, the piperazine topology in dasatinib 
only has substituents on the nitrogen atoms. 
1.1.2 Relevance of Ketopiperazines 
Piperazine derivatives are sought after not only for their potential biological activity but 
also intermediates for synthetic applications.13 One of such derivatives is the ketopiperazine, 
which is resident in synthetic and natural FDA-approved pharmaceuticals. Although, not as 
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predominant as the reduced piperazine scaffold, nature’s bias toward this motif demonstrates 
potential. Examples of ketopiperazines in FDA-approved pharmaceuticals can be seen in Figure 
1-3.  
 
Figure 1-3 Examples of monoketopiperazines found in FDA-approved drugs 
Praziquantel (Biltricide®) is a popular drug used to treat schistosomiasis caused by 
Schistosoma mansoni (S. mansoni) or Schistosoma haematobium (S. haematobium).14 These two 
fresh water-born parasites lead to intestinal or urogenital schistosomiasis, respectively. There are 
currently around 207 million people affected by it globally of which around 85% live in sub-
Saharan Africa region. This parasitic disease is considered a neglected tropical disease (NTD). 
One of the main hurdles of praziquantel has been to verify its safety and efficiency in children. 
Recent studies have proven its efficiency against schistosomiasis in both schoolchildren in 
Ethiopia15 and pre-school aged children in Kenya.16 Praziquantel is composed of a tricyclic 
azaheterocylic motif. The piperazine ring itself is tetrasubstituted and has a stereocenter which 
introduces a challenge for synthetic approaches. Although sold as a racemic mixture, studies 
indicate that the R-enantiomer is more biologically active than the S-enantiomer.17 
Dihydroergotamine (Migranal®) is a semi-synthetic pharmaceutical used in the treatment of 
acute migraines. It is a derivative of ergotamine which is isolated from a fungi of the genus 
Claviceps. Dihydroergotamine acts as an agonist to various serotonin (5-HT) receptors including 
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-1B, -1D and -1F receptor and adrenergic and dopamine receptors.18 In contrast to ergotamine, 
dihydroergotamine users exhibit less side effects such as nausea, vomiting and undesired 
vasoconstriction. The piperazine ring on dihydroergotamine is highly substituted with all the 
carbon atoms having at least one substituent on it which reiterates the importance of finding 
synthetic pathways to highly carbo-functionalized piperazines. 
1.2 Frequently Encountered Challenges in Synthetic Organic Chemistry 
The abundance of azaheterocycles in FDA-approved pharmaceuticals had led to 
exploration of step-economical, cost-saving and high-yielding synthetic strategies for their 
construction and post-diversification. In general, three challenges are associated with the 
efficient construction of azaheterocycles, namely, chemoselectivity, regioselectivity and 
stereoselectivity. 
1.2.1 Importance and Overcoming: Chemoselectivity 
Chemoselectivity is the preferential reaction of a chemical reagent with one of two or 
more different functional groups. Chemoselectivity allows bond construction with increased 
synthetic efficiency since it obviates the need for functional group protection and oxidation 
adjustment. There have been reagents developed for chemoselective reactions such as the 
Schwartz's reagent which is a zirconium based species. Figure 1-4 illustrates the allylation of an 
amide, which was chemoselectivity implemented using the Schwartz reagent.19 This was done in 





Figure 1-4 Chemoselective allylation of amide 1 
1.2.2 Regioselective Functionalization 
Regioselectivity refers to the site-selective addition of an unsymmetrical reagent to an 
unsymmetrical substrate. A prevalent form of regioselectivity is that of C(sp3)-C(sp3) bond 
formation on unsymmetrical alkenes. Figure 1-5 illustrates Hou’s work on 
hydroaminoalkylation of N-methylpiperidine with styrene derivatives and alkyl olefins.20 In both 
cases, the reaction conditions were identical, featuring a scandium transition metal. Aryl and silyl 
alkenes resulted solely in linear product 6 while alkyl alkenes resulted in branched products such 
as 7. 
 
Figure 1-5 Substrate controlled regioselective hydroaminoalkylation of alkenes 
1.2.3. Stereoselectivity and its Relevance in the Pharmaceutical Industry 
Stereoselectivity refers to the spatial-selective functionalization of molecules with same 
molecular formula and connectivity. Steroselectivity is a vital concept that synthetic organist 
chemists take into account when designing an efficient retrosynthesis for core structures that are 
seen in pharmaceuticals. Of the trinity, stereoselectivity poses arguably the greatest challenge in 
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drug design. Currently, the FDA requires pharmaceuticals to be at least 95:5 enantio- or 
diastereopure. The importance of steroselectivity can be seen in a variety of pharmaceuticals 
including ketamine21, thalidomide22, albuterol23 and dobutamine24 (Figure 1-6). 
 
Figure 1-6 Examples of stereocenter containing FDA approved pharmaceuticals 
 
Recently, the FDA-approved esketamine, the (S) enantiomer of ketamine, as an intranasal 
treatment for major depressive disorder (MDD).25  Ketamine itself, is used as an analgesic, 
anesthetic, and antidepressant. The mode of action of ketamine is as an antagonist of the N-
methyl-D-aspartate (NMDA) receptor. Esketamine has up to an eight-fold higher affinity for 
NMDA receptors than arketamine.26 There have been studies performed on both animals and 
humans that showed that arketamine shows higher and longer-lasting antidepressant 
effectiveness in animal models.27 Yet, esketamine displayed more analgesic and anesthetic 
activity in human trials.28 The interest in esketamine stems from less psychotomimetic and 
dissociative effects seen for it than from the racemic mixture and arketamine. Relative to the 
racemic mixture and arketamine, esketamine reduces drowsiness, lethargy, impairment of 
cognitive capacity, concentration capacity and primary memory loss.29 Exploration of 
stereoselective reactions is crucial since many of these compounds have significant 
pharmaceutical values. 
The concept of stereoselective functionalization has been explored by many organic 
chemists and has led to the discovery of reactions that give high yields of a single stereoisomer. 
There has been success on the formation of C(sp3)-C(sp3) bonds that are both regio- and 
stereoselective through hydroalkylation. As seen in Figure 1-7, Goldfogel obtained products 
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such as 10, which bear vicinal stereocenters in highly diastereoselective form from an oxazolone 
8 and a 1-substituted-1,3-diene 9.30 
 
Figure 1-7 Diastereoselective branched hydroalkylation of dienes onto oxazolones 
1.3 Diversity-Oriented Synthesis 
Diversity-Oriented-Synthesis (DOS) in organic chemistry has become a popular method 
to follow. The DOS method allows for an investigation of pharmaceutical value for structurally 
similar compounds. Three elements of diversity in the DOS method are the building blocks, 
stereochemistry, and molecular skeleton that can be generated. In many cases the building 
blocks/ starting material are highly affordable and can be synthetically transformed into small 
complex molecules. The other main type of synthetic approach is Target-Oriented-Synthesis 
(TOS), which is used for total synthesis of compounds such as natural products. Although useful 
for the synthesis of compounds with known biological activity, the time commitment can be 
discouraging. 
 
Figure 1-8 Comparison between TOS and DOS methods 
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One of the merits of DOS is the ability to produce a vast library of small molecules from 
a common precursor in a timely manner (Figure 1-8). Additionally, a variety of prevalent and 
highly coveted scaffolds found in pharmaceuticals can be used as the backbone and be easily 
manipulated. Small molecules are very important in the pharmaceutical field and are an 
intriguing research area. Another virtue of DOS is the sequential engagement of the produced 
compounds to structure activity relationship (SAR) studies. Unfortunately, the DOS approach 
can be thought of as a blind approach with the possibility of none of the produced compounds 
showing bioactivity. The DOS method takes advantage of the numerous examples of subtle 




1.3.1 Structure Activity Relationship (SAR) studies 
As seen in Figure 1-9, the three piperazine-containing drugs are HIV integrase strand 
transfer inhibitors (INSTI) that contain a tricyclic piperazine motif. In this tricyclic motif there is 
a difference in the ring’s size between the three drugs. Aside from the ring size difference, 
bictegravir has an extra fluorine atom. Prime characteristics contributing to the success of these 
drugs are their high intracellular half-life, absence of a booster drug, lack of negative interactions 
between other anti-retroviral drugs and tolerance towards resistance from HIV-1 strains.31 
Booster drugs are known to increase the desired effect of other drugs. In HIV treatment, booster 
drugs include ritonavir (Norvir®) and cobicistat (Tybost®). Success of these similar structured 
INSTIs can be attributed to the addition of the fluoro-substituted benzyl group that can bind with 
hydrophobic pockets near the active site and the presence of three chelating oxygen atoms that 
can coordinate to Mg2+ ions.32 
 
 
Figure 1-9 Example of structurally and bioactive similar HIV integrase strand transfer inhibitors 
Dolutegravir (Tivicay®) was FDA approved in 2013 and is administered as Triumeq® 
(Abacavir/dolutegravir/lamivudine) or Juluca® (dolutegravir/rilpivirine).33 It has proven 
effective in the treatment for HIV/AIDS in pediatric patients34, transmittance prevention from 
infected mother to child35 and individuals whose current treatment was inadequate.36 Moreover, 
it is used as a once-daily dosing option for first time treatment patients. The main structural 
difference of dolutegravir is the six-membered O-heterocycle fused to the piperazine ring. 
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Bictegravir (Biktarvy®) is used in the treatment of HIV-1 infected in adults as a first 
treatment option or replacement for a virological suppressed treatment.37 Biktarvy was FDA 
approved in 2018 and is administered once-daily in combination with emtricitabine and tenofovir 
alafenamide. Furthermore, it shows superior antiviral activity against HIV-1 isolates with 
advanced INSTI resistance when compared to dolutegravir. The ring structure on this drug is 
unique since it is bridged [3.2.1]octane containing two heteroatoms. 
Cabotegravir is currently in phase 3 for FDA approval and can take on two different 
forms: a long-acting nanosuspension and tablets.38 The main difference being the administration 
time and route which are monthly or quarterly subcutaneous or intramuscular for the 
nanosuspesnion or daily for oral tablets. It has similar characteristics as dolutegravir yet it has a 
longer half-life. The longer half-life can be attributed to the rigid 5-membered ring it possesses in 
contrast to the 6-membered ring on dolutegravir.38 Moreover, cabotegravir has the potential to be 
utilized as both a treatment and prevention option.39  
A common study performed on the three drugs was to assess antiviral activity in a short-
term monotherapy of 10 days.40–42 Change of HIV-1 RNA present after 11 days was recorded at 
a scale of log10 copies/mL.  Dolutegravir doses were 2, 10 and 50 mg which resulted in a 
decrease of HIV-1 RNA of 1.51, 2.03 and 2.46, respectively. Bictegravir results were 1.45, 2.08, 
2.06 and 2.43 decrease of RNA for 5, 25, 50 and 100mg, respectively. Cabotegravir quantities 
were 5 and 30 mg which resulted in the RNA decrease of 2.2 to 2.3, respectively. The results 
indicate that Dolutegravir works the best at 50 mg when compared to bictegravir and 
cabotegravir. Surprisingly, the only non-FDA approved drug demonstrated similar depletion of 
HIV-1 RNA at both small and large quantities. Additionally, all three drugs were well tolerated 
with no safety issues. 
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1.4 Current approaches towards functionalized piperazines 
There is a notable trend within synthetically derived FDA-approved piperazine 
containing drugs, which is the lack of functionalization on the carbon atoms. Currently, around 
80% of FDA-approved piperazines contain substituents only on the nitrogen atoms.43 This 
adversity has been reduced by introducing functionality on diamine or amino acid derived 
acyclic precursors and α-C–H functionalization on intact piperazines. 
1.4.1 Tin (Sn) Amine Protocol (SnAP) and Silicone Amine Protocol (SLAP) reagents 
A well-established method for formation of substituted piperazines was developed by 
Bode using Tin (Sn) Amine Protocol (SnAP) reagents (Figure 1-10).44 A combination of SnAP 
reagents (11) and aldehydes (12) are used to construct multiple azaheterocycles, including 
thiomorpholines, morpholines, and piperazines. The ability to use electron-poor, electron-rich, 
hetero-aromatic, and aliphatic aldehydes along with possible addition of methyl groups on the 
SnAP reagent has attributed to the outstanding contribution this protocol has made in 
constructing N-heterocycles including piperazines. An intermediate imine is formed between the 
SnAP reagent and aldehyde. At this stage, there is an addition of Cu(II) which helps form a stable 
radical that can undergo 6-endo cyclization with the intermediate imine to form the 
functionalized piperazines. Recently, a synthesis yielding higher carbon functionality was 
reported using cyclic ketones (14) and SnAP reagent, which resulted in a ketimine intermediate 
and ultimately a spirocyclic compound containing a piperazine (15).45 Unfortunately, the use of a 
toxic tin reagent has been a major downfall in the protocol. Figure 1-10 illustrates how this issue 
has been mitigated by the introduction of Silicon Amine Protocol (SLAP) reagents (16) by the 




Figure 1-10 Bode’s work with SnAP (top and middle) and SLAP reagents (bottom) on 
piperazines ring 
1.4.2 Annulation reaction via phenylvinyl sulfonium salts 
Cycloadditions are a common way to form six-membered rings and this does not exclude 
N-heterocycles. Aggarwal’s group demonstrated a [4 + 2] annulation reaction between β-amino 
amines and diphenylvinylsulfonium triflate to construct the piperazine motif. In the initial 
protocol there are two major setbacks (i) the preparation and scalability of the vinylsulfonium 
salt due to its sensitive and oily nature and (ii) inability for substituents to be placed on both 
sides of the ring. To overcome the first obstacle, conditions for in-situ generation of the 
vinylsulfonium triflate were investigated and optimized. This was done by using a bromoethyl 
sulfonium salt (18) and treating it with sodium hydride.47 The second setback was addressed by 
using α‑phenylvinylsulfonium salts (20), yet only phenyl groups were appended and yields and 




Figure 1-11 Two approaches towards functionalized piperazines via in-situ generated 
phenylvinylsulfonium salts (top) and pre-generated α‑phenylvinylsulfonium salts (bottom) 
 
1.4.3 Transition Metal Catalyzed Approaches 
Transition-metal based catalysis has also been employed to form highly substituted 
piperazines. This can be seen in the works of Wolfe and Nelson that used palladium catalyst 49 
and gold catalyst50, respectively (Figure 1-12). The merits behind these works is the asymmetric 
products that are achieved. Notably, Wolfe’s work is highly modular and stereoselective with the 
final product (28) having four substituents around the ring. This reaction uses a Pd-catalyst for 
carboamination across an alkene. This forms two new vicinal bonds, an intramolecular C(sp3)-
N(sp2) bond and intermolecular C(sp3)-C(sp3) bond to produce the piperazine. Additionally, 
Wolfe’s group demonstrated a vast selection of functionalization on the nitrogen atoms unlike 





















































Figure 1-12 Two transition metal-based strategies towards functionalized piperazines 
1.4.4 Formation of monoketopiperazines 
The interest for highly substituted piperazines is continuous which has lead groups to 
investigate piperazine derivatives such as vicinal ketopiperazines. This has led to multiple 
methods for the construction of this motif such as those employed by Dömling51, Viso52, 
Denoyelle53, Procopiou54, Powell55 and Kokotos56. Although useful, many of these tactics have 
major setbacks including lack of stereocontrol, lack of modularity, costly catalysts and/or 
excessive steps. It is important to mention that Viso’s synthesis, although step heavy, allows for 
isolation of various ketopiperazine derivatives along the way, all of which are potential 
pharmaceuticals.52 The acyclic precursors are highly accessible and can be treated with 
chloroacetyl chloride to generate N-sulfinyl ketopiperazines (29). Elimination of the sulfur 
moiety renders an imino ketopiperazine (30) which was used to add various alkyl tethers by 
nucleophilic additions. There is a slight drawback of the reaction since it requires a protecting 
group that is kept throughout. The Viso group demonstrated cyclization to a piperazine without 





















31a; R1 = 1-Napth, R2=P=H, 31% yield
 
Figure 1-13 Preparation of functionalized monoketopiperazines 
1.4.5 Piperazine formation through a cascade reaction 
In organic chemistry, the pursuit for cascade reactions is significant since it lowers the 
number of steps and can increase the overall yield. This strategy has been employed by the 
Carreira group through ring expansion of spirocycles (34) derived from 3-oxetanone (33) to form 
N-heterocycles including morpholines, thiomorpholines and piperazines (Figure 1-14).57 A 
combination of two known forms of reactivity (i) ring strain and (ii) Lewis basicity of ethers 
were used as their starting point to explore cascade reaction conditions. A cyano nucleophile was 
appended onto the piperazine via trimethylsilyl cyanide (TMSCN) which allows for post-
diversification of the piperazine.  
 
Figure 1-14 Ring expansion protocol for functionalized piperazines 
1.5 Peripheral functionalization of intact piperazine rings 
Formation of highly functionalized piperazines from acyclic precursors is well 
established yet there lies an interest in peripheral functionalization on the piperazine ring itself. 
There are currently three main methods of α-C–H functionalization on piperazines: transition-
metal-catalysis, lithiation trapping and photoredox catalysis.  
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1.5.1 Hydroaminoalkylation promoted by transition metal catalyst  
As previously mentioned transition metal (TM)-catalysts are known to produce highly 
substituted piperazines from acyclic precursor. Fortunately, TM-catalyzed functionalization falls 
at both ends of the spectrum and can also be used for α-C–H functionalization on intact 
piperazines. As seen in Figure 1-15, through the use of a transition metal-catalyst such as 
tantalum, C(sp3)-C(sp3) bonds have successfully been formed using simple alkenes, styrenes and 
cycloalkenes via hydroaminoalkylation.58 This method has resulted in diastereoselective α-C–H 
functionalization on piperazines yet it has two main shortcomings: (i) costly TM-catalysts and 


















Figure 1-15 Synthesis of carbo-substituted piperazines by tantalum catalyzed 
hydroaminoalkylation 
 
1.5.2 Enhanced method for lithiation-trapping on piperazines 
Direct α-lithiation and electrophile trapping for α-functionalization of N-Boc 
azaheterocycles involves more concrete and atom-economic procedures making it a prevalent 
used method. Originally, McDermott established the possibility of lithiation-trapping chemistry 
on piperazines.59 Unfortunately, yields and enantioselectivity were low. O’Brein proposed that 
the setbacks in McDermott’s work included (i) the electrophile and (ii) the second N-substituent. 
Development of an enantioselective lithiation-trapping protocol was rightfully anticipated after 
addressing the limitations.60,61 Presence of a sterically hindered N-alkyl group such as N-tert-
butyl or N-α-methylbenzyl increased the yield with N-α-methylbenzyl being preferred due to it 
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being readily removable. As suspected by O’Brien, the electrophile chosen was crucial for an 
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42a. E = SnBu3, 94% yield, 93:7 dr
42b. E = SpTol, 86%, 95:5
42c. E = COC6H5, 86%, 93:7
42d. E = allyl, 79%, 95:5








R = H or E (not observed)
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Figure 1-16 McDermott (top) and O’Brien (bottom) approach towards lithiation-trapping on 
piperazines 
 
1.5.3 Functionalization of piperazine by photoredox activation 
Lately, direct photoredox C–H activation of the α-position of amines, piperidines, 
morpholines and N-Boc piperazines has been an implemented for  functionalization.62 Excitation 
of an iridium III complex, such as Ir(ppy)3 by a photon from a 26-W light source generates an 
excited *IrIII(ppy)3  complex which is a reductant. A single electron transfer (SET) with an arene 
(45) produces an arene radical anion species and IrIV(ppy)3, the latter of which is an oxidant. 
Likewise, the newly formed complex can undergo a SET with an azaheterocycle (44) to generate 
a radical cation leading to the radical-radical coupling and formation of product. Unfortunately, 
photoredox catalysis for direct α-C–H functionalization of piperazines has not been highly 
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Figure 1-17 Functionalization of intact piperazine ring by photoredox chemistry 
1.5.4 Enolate functionalization of piperazines 
Although these three previously mentioned strategies appear to be the most popular other 
methods are being introduced for α-C–H functionalization. Enolate functionalization has recently 
been used as a method to obtain substituted piperazines. In 2012, enolate functionalization on 
piperazines was demonstrated as an intermediate towards homopiperazines.63 Cossy’s work 
focuses on the formation of piperidines and azepanes with a sole example on the piperazine 
(Figure 1-18). Although the enantioselectivity is high on piperidines and azepanes, it was 
unreported for the piperazine example. This of course should not lead others from this type of 
carbon functionalization. Figure 1-18 also demonstrates Stoltz approach towards 
enantioselective decarboxylation allylic alkylation to produce highly substituted piperazines 
using enolate functionalization. There were two main setbacks as yields were low and hardships 
were faced in post-diversification of the N-substituents.64 However, both of these setbacks were 
addressed mainly by replacing the previous benzyl group with a Boc group. In this instance, the 
electron-withdrawing nature of the Boc group reduces the nucleophilicity of the nitrogen, 





Figure 1-18 Enolate alkylation as a precursor for ring expansion (top) and for enantioselective 
synthesis of gem-substituted piperazines (bottom) 
 
 1.6 Significance of fluorine chemistry 
In the previously mentioned syntheses, it was demonstrated that a fluorine atom can be 
incorporated onto the piperazine containing compound. Figure 1-19 illustrates an array of 
piperazine and fluorine containing compounds including those from Bode’s SnAP (13a) and 
SLAP protocols (13b), Wolfe (53), Nelson (54), Viso (55), and Stoltz (56) works. Integration of 
fluorine atoms in possible drug candidates has become a popular practice owing to its 
electronegativity, size, stability of C-F bond vs a C-H bond and lipophilicity compared to 
hydrogen.66 A fluorine atom is known to increase the bioavailability of drug sand drug 
candidates by three different modes: improving metabolic stability, increasing binding affinity 





Figure 1-19 Representation of fluorine containing piperazines from previous examples 
Metabolic stability is a challenge that is continuously faced in the drug discovery realm 
which can be confronted by the addition of fluorine at the site of metabolic attack. Fluorine 
atoms stabilize the site of substitution, as well as adjacent and distal sites by inductive/resonance 
or conformational/electrostatic effects. Specifically, this can inhibit oxidative metabolism since a 
C–F bond is more resistant to metabolism than a C–H bond. A fluorine atom can take part in 
hydrogen bonding which increases binding affinity and stabilizes the compound at the drug-
receptor site. Many physiochemical properties are effected by a fluorine such as the pKa, dipole 
moment, chemical reactivity, stability, cLogP, ADME properties and solubility of the compound. 
The inductive effect attributed to F atoms can lower the pKa of the compound including 
heterocycles which become less basic with β-, γ- and δ- fluorine substituents. This can help in 
overcoming the lack of diffusion of drugs such as in the brain blood barrier.  Fluorine atoms also 





1.6.1 Relevance of fluorine containing piperazine scaffolds 
As seen in Figure 1-20, there are currently a number of examples of fluorine present in 
compounds containing a piperazine ring.  
 
Figure 1-20 Examples of fluorine and piperazine containing bioactive compounds 
Sitagliptin (Januvia®) is a competitive inhibitor of dipeptidyl peptidase 4 (DPP-4) and is 
used to treat type 2 diabetes. Inhibition of DPP-4 increases activity of glucagon-like peptide-1 
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) which are involved in 
stabilizing and maintaining the proper amount of insulin and glucagon.68 There are minimal side 
effects contributed with sitagliptin such as cardiovascular trouble69 and weight gain70 that can be 
seen in other similar drugs. Sitagliptin contains a trifluoromethyl containing triazole-fused 
piperazine along with a trifluorinated aryl ring. 
Vestipitant is a neurokinin-1(NK-1) receptor antagonist which binds substance P with 
potential for the treatment of insomnia and tinnitus. Substance P is a neurotransmitter and a 
neuromodulator. The effectiveness of vestipitant has been demonstrated on primary insomnia 
which improved sleep continuity by reducing wake after sleep onset (WASO), increasing total 
sleep time (TST) and increasing rapid eye movement (REM) sleep.71 These type of receptors are 
also located in the inner ear giving confidence for its potential treatment of tinnitus.72 There are 
three fluorinated positions including two trifluoromethyl groups and one monofluoro atom. 
Unlike other piperazine rings, one nitrogen atom does not have a substitutient. 
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1.6.2 Synthetic applications focused on fluorinated piperazines 
As previously stated, multiple groups have incorporated fluorine atoms yet the focus was 
not precisely on this modification. Bode adapted the SnAP protocol to an azido SnAP protocol to 
facilitated condensation between regular SnAP reagent and acyclic ketones (Figure 1-21).45 
Intermediate ketimines are formed by Staudinger and aza-Wittig reactions. Unfortunately, the 
three examples resulted in low yields (43% highest).  Likewise, Figure 1-21 also demonstrates 
Sánchez-Roselló reported fluorination of piperazines through the Ruppert-Prakash reagent 
trifluoromethyltrimethylsilane (TMSCF3).
73 Nucleophilic addition of the Ruppert−Prakash 
reagent has been a popular method in organic synthesis to add a trifluoromethyl group. Ellman’s 
N-(tert-butanesulfinyl)imine (60) was the key intermediate for addition of the trifluoromethyl 
group. The resulting diastereoselective –CF3 bearing piperazines are unique and unexplored, 
unfortunately the described synthesis is step-costly. The main issue being that the synthesis of 
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1.7 Statement of Purpose: The specific aims of this thesis are as follows: 
• Develop a modular and stereoselective protocol for the construction and post-
diversification of vicinally functionalized and fluorinated piperazines. 






CHAPTER 2: MODULAR ACCESS TO VICINALLY FUNCTIONALIZED AND 
FLUORINATED PIPERAZINE DERIVATIVES USING A READILY AFFORDABLE 
CYCLIC ANHYDRIDE 
2.1 Introduction 
The prevalence of the piperazine ring in natural products and FDA-approved 
pharmaceuticals has granted it the status of a privileged scaffold. This title is aggrandized by the 
variety of biological activities it exhibits, including antidepressant, antipsychotics, antibacterial, 
and antiretroviral properties (Figure 2-1). 
 
Figure 2-1 Examples of bioactive (keto)piperazines 
The addition of a fluorine atom on organic compounds has become a common tactic to 
alter physicochemical properties and potentially enhance bioavailability.66,67,74 Specifically, 
fluorine atoms substitute hydrogen atoms in multiple ways including single hydrogen, methyl 
group and displacement of multiple hydrogens around a phenyl ring. This is explained by the 
relative small size of a fluorine atom (1.47 Å) and its high electronegativity.74 Therefore, 
merging these two components can be beneficial to the synthetic and medical communities.  
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As previously stated, methods for carbo-functionalization on piperazines are relatively 
scarce. Nevertheless, their prevalence in natural products and FDA-approved pharmaceuticals 
continues to attract the attention of many organic chemists. Some notable strategies include 
Bode’s SnAP44,45 and SLAP46 methodology, Agarwaal’s [4 + 2] cycloaddition using 
phenylvinylsulfonium salts47,48,75, transition-metal catalysis49,50,58, enolate functionalization as 
employed by Stoltz64,65, etc. Although successful, the necessity of costly catalysts, potential 
health hazards, step-uneconomical, limited modularity and lack of post diversification 
opportunities has maintained an interest for improved synthetic pathways to the piperazine 
scaffold. 
The Castagnoli-Cushman reaction (CCR) has been identified as a viable way to construct 
vicinally functionalized azaheterocycles in a modular and step-economical fashion. Advantages 
of the CCR is the use of feedstock chemicals such as aldehydes, amines and anhydrides, the 
highly diastereoselective and modular nature, which bodes well for structure-activity relationship 
(SAR) studies. Initial studies on the CCR were done through reactive cyclic anhydrides such as 
homophthalic anhydride76 (Figure 2-2A) and succinic anhydride.77 The scope of the CCR 
anhydride has also recently been expanded to functionalized sulfone- and cyano-substituted 
pyrrolidines78,79, piperidines80, morpholines and thiomorpholines81 and benzannulated 
azepanes.82 
Our group has contributed to the success of the CCR by reacting commercially available 
cyclic anhydrides such as glutaric anhydride and digylcolic anhydride with 1,3-azadienes to 
generate highly functionalized allylic piperidines83 and morpholines,84 respectively. The method 
included subjecting the lactamoyl ester precursor to a Vilsmeier-Haack reaction to append two 
functional handles; a chloride and a formyl group. The chloride handle was subsequently 
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employed as a functional handle for cross-coupling to arrive at 2,3,5,6 dihydropiperidines via 
transition-metal catalyzed cross-couplings.83 This highly modular approach allowed for efficient 
alkynylations, alkenylations and arylations of tetrahydropyridines. Additionally, we have also 
been able to access functionalized bicyclic morpholines.84 This was achieved by subjecting the 
lactamoyl esters to a Grignard addition to form a tertiary alcohol. The resulting lactam-bearing 
alkenol was engaged in a copper-catalyzed intramolecular dehydrogenative alkoxylation. 
In recent years, Krasavin and co-workers have revealed that tosyl-substituted N-
heterocyclic anhydrides such as 4 (prepared in at least three steps from commercially available 
diacids) participate in the CCR with aryl aldimines of type 5, leading to adducts such as 6 
(Figure 2-2B).81 Gleaning from these prior reports, and in the wake of our recent success with 
CCR methodology,85,86 we sought to evaluate the performance of novel and easy-to-prepare N-
heterocyclic anhydride 7 in annulation protocols featuring several reactive partners, including 
lactim ethers, imidoyl chlorides, aryl aldimines such as 5, and 1,3-azadienes of type 9 (Figure. 2-
2C/D). We reasoned that successful implementation of the planned strategy would likely expand 
the chemical space for the discovery of new fluorinated piperazine pharmacophores. Detailed 








2.2 Results and Discussion  
 
Figure 2-2. Previous studies on the CCR and our proposed plan for accessing fluorinated and 
vicinally functionalized (bicyclic) ketopiperazines 
 
We initiated studies on the construction and post-diversification of vicinally 
functionalized fluorinated ketopiperazines using commercially available lactim ether 2a as the 
model annulation partner for 7 (prepared in one step from commercially available iminodiacetic 
acid, see Scheme 2-1). Encouragingly, when an equimolar mixture of 2a and 7, in benzene, was 
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heated to 90 oC, a clean chemoselective annulation reaction occurred and CCR product 8a was 
obtained in 49% yield along with unreacted starting materials (Table 2-1, entry 1). Reaction 
optimization was carried out and it was established that toluene out-performs other reaction 
media (e.g., benzene, xylenes, chlorobenzene, 2-MeTHF, DMF and 1,4-dioxane). Much like 
homophthalic anhydride 1, the strong electron-withdrawing prowess of the trifluoroacetyl group 
presumably enhances the α-CH acidity of 7 and renders it a competent substrate for the 
annulation. Of note, [6,6]-bicycles of type 8a constitute the core of several pharmaceuticals, 
including the most recent antiretroviral approved for the treatment of HIV-1 infection (i.e., 
dolutegravir, see Figure 2-1). 
Table 1 Optimization of the annulation of lactim ether 2a with anhydride 7
 
As further illustrated in Scheme 2-1, 7 reacts satisfactorily with homologous lactim ether 
2b to furnish [7,6]-bicycle 8b. The ability to retain the methoxy group is noteworthy given that 
cyclic N,O-aminals of type 8a/b are suitable synthons for further diversification whereby the 
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Scheme 2-1. Synthesis and annulation of anhydride 7 with lactim ethers 
 
Scheme 2-2. Annulation of 7 with imidoyl chlorides 
Imidoyl chlorides such as 2c/d react competently with 7 (Scheme 2-2). However, in this 
scenario, a cascade process ensues whereby decarboxylation and elimination are accompanied by 
concomitant chlorination of the inherently nucleophilic C3 position of the bicyclic enaminone 
(see 8c/d). The mechanistic nuances of this cascade process are still being fleshed out.  
Recognizing the merits of the Castagnoli-Cushman reaction77 (e.g., the use of feedstock 
chemicals such as amines, aldehydes and cyclic anhydrides to readily access nonplanar sp3-
enriched core structures bearing vicinal stereocenters), the performance of fluorinated anhydride 
7 in annulation protocols featuring aryl aldimines was evaluated. In the event, we found that 7 
undergoes a stereoselective and efficient cycloaddition with aryl aldimines of type 5 followed by 
methyl esterification to furnish vicinally functionalized ketopiperazines such as 10 (Scheme 2-
3). In all cases, the trans adducts were obtained as the predominant diastereomer (as judged by 
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coupling constant analyses). The relative configuration is also consistent with Krasavin’s 
complementary findings on N-tosyl anhydride 4.81 Imines harboring N-benzyl- or N-alkyl 
substituents outperform their N-aryl counterparts (see 10b vs 10c). The reaction tolerates mainly 
electron-rich aryl aldimines, including ones bearing benzyloxy (see 10j/m) and allyloxy groups 
(see 10k). As exemplified through the synthesis of thiophene-bearing 2-oxopiperazine 10p, 
heteroaryl aldimines react satisfactorily with 7. The successful annulation of 7 with 5 is 
noteworthy given that the N-Boc congener is an incompetent reactive partner.81 
 
Scheme 2-3. Annulation of 7 with diversely N-substituted aryl aldimines 
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Following successful construction of a small library of vicinally functionalized 
fluorinated benzylic 2-oxopiperazines, we next sought to prepare their allylic congeners. The 
installation of an alkenyl motif on the skeleton of a piperazinic acid could pave the way for 
harnessing reactivity modes such as halolactonization,91 dehydrogenative alkoxylation,84 and 
dehydrative coupling.86 Towards this end, the amenability of 1,3-azadienes of type 9 to a CCR 
with 7 was explored. We were cognizant of the notoriously promiscuous reactivity of 9 with 
cyclic anhydrides bearing relatively acidic α-CH protons. For example, homophthalic anhydride 
reacts with 9 to afford a plethora of products, including Tamura-like, Castagnoli-like, and 
Perkin-type products.92 Meanwhile, 9 reacts efficiently with glutaric anhydride and diglycolic 
anhydride to furnish exclusively the CCR products.85 In the event, 7 reacted chemoselectively 
with several differentially substituted 1,3-azadienes to afford the vicinally functionalized allylic 
ketopiperazines depicted in Scheme 2-4. Strikingly, unlike 7, tosyl-bearing anhydride 4 reacts 
non chemoselectively with 9 and furnishes a complex mixture. This result further highlights that 
minor structural modifications of the anhydride component can lead to profound changes in 




Scheme 2-4. Annulation of 1,3-azadienes with N-trifluoroacetyl anhydride 7 
A potentially beneficial aspect of this methodology is the scalable nature of the reactions 
given that products such as 8a, 8d, 10m, 11a, and 11c have been prepared in gram scale, without 
any compromise in efficiency. This has set the stage for post-diversification studies. For 
example, fully substituted dihydro-1,4-diazines are affordable when piperazinonates such as 11c 
are subjected to a lactam-selective Vilsmeier-Haack reaction (Scheme 2-5, see 12). This 
outcome illustrates an example of scaffold hopping through the construction of a diazinic 
topology from a piperazine, which is resident in various alkaloids that exhibit a wide array of 
biological activities, including antitumor and antiparkinsonian properties (e.g., saframycin).93 
One of the inherent limitations of CCR methodology is the futility of imines derived from 
enolizable aldehydes such as hydrocinnamaldehyde given that their enamine tautomers readily 
undergo acylation reactions with the anhydride component.81 Using the current approach, this 
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limitation can be side-stepped through catalytic hydrogenation of the alkenyl motif resident in 
allylic lactamoyl ester 11a (see 13). Sodium borohydride-assisted chemoselective reduction of 
the ester group present in 10m and concomitant removal of the trifluoroacetyl group affords β-
aminoalcohol 14 in good yield. We have found that removal of the trifluoroacetyl group under 
very mild conditions is achievable when a mixture of 10b in dichloromethane is stirred at room 
temperature in the presence of pyrrolidine (see 15). 
 
Scheme 2-5. Elaboration of functionalized fluorinated ketopiperazines 
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2.3 Conclusion: In summary, a small library of vicinally functionalized fluorinated bicyclic, 
benzylic, and allylic ketopiperazines has been constructed by engaging a readily affordable 
cyclic N-trifluoroacetylated anhydride in annulative protocols with lactim ethers, imidoyl 
chlorides, aryl aldimines, and 1,3-azadienes. The direct employment of cheap commodity 
chemicals such as amines, aldehydes and N-heterocyclic anhydrides in this multicomponent, 
chemoselective, and diastereoselective annulation protocol bodes well for future applications in 
medicinal chemistry. Post-diversification of the cycloadducts to piperazinyl methanols as well as 
highly functionalized dihydro-1,4-diazines has been accomplished. Leishmanicidal evaluation of 
these functionalized ketopiperazines is underway and the results will be disclosed in due course. 
2.4 Methods: General Procedure 
All experiments involving air and moisture sensitive reagents were carried out under an 
inert atmosphere of nitrogen and using freshly distilled solvents. Column chromatography was 
performed on silica gel (230-400 mesh). Thin-layer chromatography (TLC) was performed using 
Silicycle SiliaplateTM glass backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) 
and visualized using UV (254 nm) or KMnO4 stain. Unless otherwise indicated, 
1H, 13C, and 
DEPT-135 NMR, COSY 45, HMQC, and NOESY spectra were acquired using DMSO-d6, 
CD3OD or CDCl3 as solvent at room temperature. Chemical shifts are quoted in parts per million 
(ppm). HRMS-EI+ data were obtained using either electronspray ionization (ESI) or electron 
impact (EI) techniques.  
2.4.1 General Procedure A: Synthesis of Trifluoroacetyl cyclic anhydride 
To a stirring suspension of iminodiacetic acid (1 mmol) in dry ethyl acetate (15 mL) 
trifluoroacetic anhydride (TFAA) (3 equiv) was added. The reaction mixture was stirred for 3 
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days at room temperature. The mixture was washed with petroleum ether, then concentrated 
under reduced pressure to afford the trifluoroacetyl bearing cyclic anhydride. 
 2.4.2 General Procedure C/D: Synthesis of N-Benzyl cyclic anhydride 
A mixture of iminodiacetic acid (1 mmol) in acetyl chloride (3 mL) was heated at reflux 
for 48 h. The mixture was cooled to room temperature, concentrated under reduced pressure and 
washed twice with a 50:50 solution of petroleum ether and hexanes in the reaction vial.94  
2.4.3 General Procedure C: Reaction of imine component with anhydride  
A 5 mL screw-cap vial was flame-dried, evacuated and flushed with nitrogen. A solution 
of the 1,3-azadiene (1.0 mL, 0.10 M in freshly distilled toluene) was added to the vial at room 
temperature followed by anhydride 1d/e (1 equiv). The contents were placed in a pre-heated oil 
bath thermostatted 100 oC. After complete consumption of the 1,3-azadiene (as judged by TLC 
and NMR), the mixture/suspension was cooled to room temperature and washed several times 
with petroleum ether, then concentrated under reduced pressure to afford the crude cycloadducts. 
2.4.4 General Procedure D: Methyl esterification of cycloadducts 
To a stirring suspension of the acid (1 mmol), dissolved in DMF (5 mL), and K2CO3 (3 
equiv) methyl iodide (2 equiv) was added under nitrogen atmosphere. The reaction mixture was 
stirred for about 12 h (TLC monitoring). After complete conversion, it was diluted with water 
and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated in vacuo to give the desired ester, which was purified by 
flash chromatography on silica. 
2.4.5 Genreral Procedure E: Vilsmeier-Haack reaction 
To a cooled solution of DMF (6 mmol, 6 equiv) in CH2Cl2 (5 mL) at 0 
oC, phosphorus 
oxychloride (3 mmol, 3 equiv) was added dropwise. The resulting pale yellow mixture was 
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refluxed for 1 hour. A solution of the lactamoyl ester (1 mmol, 1 equiv) in CH2Cl2 (5 mL) was 
added slowly. The mixture was then cooled to room temperature and stirred for the indicated 
time period (TLC and GC-MS monitoring was used to follow the extent of the reaction). Upon 
completion, the mixture was poured into a large flask containing crushed ice. After stirring at rt 
for 60 min, the layers were separated. The mixture was extracted with CH2Cl2 twice and washed 
with brine. The combined organic layers were dried over MgSO4 for 5 min. The mixture was 





2.5 Peak Assignments 
Reaction with lactim ethers 
2.5.1 Peak Assignment for 8a  
 
 
Prepared from 2a (113.3 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using General 
Procedure C. T = 110 oC, time = 22 h. Purification: Flash chromatography on silica eluting with 
hexane/EtOAc (75:25). Yield = 247 mg, 88%.
 1H NMR (400 MHz, Chloroform-d, rotamers) δ 
4.67 (d, J = 1.6 Hz, 1H), 4.56 (s, 1H), 4.08 – 4.03 (m, 2H), 3.63 – 3.49 (m, 5H), 2.45 – 2.36 (m, 
2H), 1.73 – 1.63 (m, 4H).
 13C NMR (101 MHz, CDCl3) δ 173.69, 173.54, 171.00, 170.41, 168.26, 
168.20, 157.86, 157.66, 157.50, 157.30, 156.93, 120.45, 117.59, 114.73, 111.87, 55.36, 55.32, 
55.12, 52.77, 52.53, 49.61, 49.57, 49.47, 44.70, 44.62, 34.50, 34.45, 22.21, 22.18, 20.09, 19.98.  
2.5.2 Peak Assignment for 8b 
 
 
Prepared from 2b (127.5 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using General 
Procedure C. T = 110 oC, time = 22 h. Purification: Flash chromatography on silica eluting with 
hexane/EtOAc (75:25). Yield = 244 mg, 83%. 1H NMR (400 MHz, Acetonitrile-d3, rotamers) δ 
4.66 (s, 2H), 4.13 – 3.99 (m, 2H), 3.77 (q, J = 5.5 Hz, 2H), 3.62 (s, 3H), 2.58 (m, 2H), 1.70 – 1.64 
(m, 6H). 13C NMR (101 MHz, CDCl3) δ 178.17, 178.04, 170.48, 169.95, 168.28, 117.64, 117.60, 
114.74, 55.02, 52.85, 52.62, 49.71, 43.84, 43.81, 39.34, 29.80, 29.21, 29.13, 28.46, 23.67, 23.64.  
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2.5.3 Peak Assignment for 8c 
 
Prepared from 2c (117.6 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using General 
Procedure C. T = 100 oC, time = 18 h. Purification: Flash chromatography on silica eluting with 
hexane/EtOAc (75:25). Yield = 240 mg, 85%. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 
4.65 (d, J = 1.6 Hz, 1H), 4.50 (s, 1H), 3.57 (dq, J = 10.2, 3.5 Hz, 2H), 2.41 (dq, J = 7.2, 3.0 Hz, 
2H), 1.68-1.60 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 174.03, 174.01, 171.28, 171.13, 170.54, 
170.07, 169.95, 157.83, 157.47, 157.33, 157.11, 120.50, 117.64, 114.78, 111.92, 55.70, 55.67, 
55.52, 44.68, 44.60, 34.37, 34.34, 22.10, 22.08, 19.97, 19.87.  
 2.5.4 Peak Assignment for 8d 
 
Prepared from 2d (131.7 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using General 
Procedure C. T = 100 oC, time = 18 h. Purification: Flash chromatography on silica eluting with 
hexane/EtOAc (75:25). Yield = 258 mg, 87%. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 
4.60 (d, J = 1.8 Hz, 1H), 4.47 (s, 1H), 3.78 – 3.68 (m, 2H), 2.55 (dt, J = 10.9, 5.5 Hz, 2H), 1.60 – 
1.51 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 178.14, 178.01, 170.56, 170.04, 157.74, 157.37, 
120.59, 119.66, 117.72, 114.86, 112.00, 55.67, 55.60, 55.57, 43.76, 43.74, 39.31, 29.18, 29.08, 






 2.5.5 Peak Assignment for 10a 
 
Prepared from the imine (225 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using General 
Procedure C/D. Purification: Flash chromatography on silica eluting with hexane/EtOAc (50:50). 
Yield = 369 mg, 82%, 95:5 dr. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 7.25 – 7.03 (m, 
3H), 7.02 (ddd, J = 6.8, 4.6, 2.0 Hz, 2H), 6.97 – 6.87 (m, 2H), 6.81 – 6.71 (m, 2H), 5.44 (dd, J = 
14.5, 11.7 Hz, 1H), 4.77 (dd, J = 10.3, 2.1 Hz, 1H), 4.54 – 4.39 (m, 2H), 4.20 – 4.09 (m, 1H), 3.64 
(s, 3H), 3.35 – 3.19 (m, 4H). 13C NMR (101 MHz, CDCl3, rotamers) δ 167.17, 167.12, 163.80, 
162.95, 160.26, 160.20, 157.31, 157.10, 156.72, 156.55, 156.35, 156.18, 155.98, 155.82, 155.45, 
135.61, 135.49, 128.95, 128.89, 128.70, 128.56, 128.41, 128.25, 127.52, 127.37, 127.26, 127.15, 
120.17, 119.86, 117.51, 117.31, 117.00, 115.23, 114.96, 114.92, 114.66, 114.60, 114.45, 114.13, 
111.59, 111.27, 61.10, 61.07, 61.04, 59.16, 58.37, 58.17, 55.44, 55.41, 53.23, 53.02, 52.86, 52.64, 
48.89, 48.20, 46.67, 46.08. 
 2.5.6 Peak Assignment for 10b 
 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (25:75). Yield = 413 mg, 86%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, mixture of rotamers) δ 6.90 – 6.83 (m, 4H), 6.78 – 6.61 (m, 4H), 5.33 (dd, J = 14.4, 
11.2 Hz, 1H), 4.76 (dd, J = 9.2, 2.1 Hz, 1H), 4.52 – 4.34 (m, 2H), 4.14 – 4.06 (m, 1H), 3.70 – 3.51 
(m, 6H), 3.27 (s, 3H), 3.18 (dd, J = 14.4, 5.1 Hz, 1H). 13C NMR (101 MHz, CDCl3, mixture of 
rotamers) δ 168.15, 168.05, 167.19, 167.13, 163.67, 162.80, 160.21, 160.14, 159.60, 156.66, 
156.29, 156.13, 155.77, 130.28, 130.23, 127.58, 127.53, 127.40, 127.25, 127.19, 127.14, 117.30, 
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116.99, 114.90, 114.86, 114.17, 114.13, 61.07, 61.04, 58.90, 58.19, 58.09, 55.38, 55.35, 55.33, 
53.23, 53.02, 52.80, 52.57, 48.90, 47.60, 47.34, 46.72, 46.68, 46.05.  
 2.5.7 Peak Assignment for 10c 
 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (25:75). Yield = 294 mg, 63%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.02 (dd, J = 8.7, 3.6 Hz, 6H), 6.93 – 6.83 (m, 2H), 6.81 – 6.71 (m, 
2H), 6.75 – 6.61 (m, 2H), 5.31 (dd, J = 10.8, 2.3 Hz, 1H), 4.56 (dd, J = 18.6, 10.5 Hz, 1H), 4.43 
(d, J = 17.9 Hz, 1H), 3.73 – 3.60 (m, 10H). 13C NMR (101 MHz, CDCl3, rotamers) δ 167.87, 
167.75, 163.75, 162.90, 160.12, 160.06, 159.05, 159.02, 156.69, 156.31, 155.91, 133.21, 133.13, 
128.16, 127.85, 127.49, 127.46, 127.30, 127.20, 121.65, 117.35, 114.85, 114.78, 114.77, 114.75, 
114.49, 114.21, 114.19, 114.13, 67.17, 64.83, 63.97, 61.80, 61.77, 58.81, 55.54, 55.50, 55.42, 
55.39, 54.00, 53.78, 47.16, 47.12, 46.57. 
2.5.8 Peak Assignment for 10d 
 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (75:25). Yield = 320 mg, 77%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.08 (dd, J = 8.6, 4.8 Hz, 2H), 6.86 (dd, J = 8.5, 4.4 Hz, 2H), 5.48 (dd, 
J = 9.0, 2.9 Hz, 1H), 5.24 + 4.76 (d, J = 2.8 Hz, 1H), 4.32 – 4.11 (m, 2H), 3.89 – 3.68 (m, 6H), 
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1.36 (s, 9H). 13C NMR (101 MHz, CDCl3, rotamers) δ 167.96, 167.75, 164.21, 163.28, 159.75, 
159.68, 155.94, 155.65, 155.28, 132.00, 129.61, 129.23, 129.01, 128.66, 126.86, 126.80, 117.22, 
114.71, 114.63, 114.36, 62.73, 62.70, 60.08, 59.56, 59.37, 58.53, 57.59, 55.32, 55.30, 53.64, 53.43, 
48.03, 47.99, 47.75, 28.72, 27.99. 
2.5.9 Peak Assignment for 10e 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (60:40). Yield = 302 mg, 75%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) 7.06 (dd, J = 8.5, 5.5 Hz, 2H), 6.98 – 6.79 (m, 2H), 5.27 – 5.21 (m, 1H), 
5.13 (dd, J = 12.8, 2.5 Hz, 1H), 4.82 – 4.64 (m, 1H), 4.43 (d, J = 12.3 Hz, 1H), 3.82 – 3.69 (m, 
6H), 1.08 (t, J = 6.7 Hz, 3H), 0.83 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3, rotamers) δ 
167.62, 167.46, 163.38, 162.47, 159.78, 159.73, 156.53, 156.16, 155.58, 131.98, 130.90, 129.75, 
129.59, 129.42, 128.41, 128.18, 128.13, 126.84, 126.78, 117.22, 116.96, 114.58, 114.51, 114.36, 
114.33, 114.25, 114.15, 114.09, 113.39, 58.07, 56.46, 55.68, 55.59, 55.30, 55.27, 53.60, 53.38, 
47.04, 47.00, 46.96, 46.69, 46.60, 46.18, 19.75, 19.70, 19.59, 19.57.  
2.5.10 Peak Assignment for 10f 
 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 360 mg, 80%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.22 – 7.19 (m, 3H), 7.17 – 6.95 (m, 2H), 7.06 – 6.87 (m, 2H), 6.71 (d, 
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J = 8.3 Hz, 2H), 5.37 (dd, J = 14.4, 10.4 Hz, 1H), 4.83 (dd, J = 10.4, 2.0 Hz, 1H), 4.55 – 446 (m, 
2H), 4.12 (d, J = 11.3 Hz, 2H), 3.51 (s, 3H), 3.31 (s, 3H), 3.21 (dd, J = 14.5, 4.9 Hz, 1H). 13C NMR 
(101 MHz, CDCl3, rotamers) δ 168.15, 168.09, 167.13, 167.08, 163.83, 162.97, 159.64, 157.69, 
157.32, 156.70, 156.33, 156.12, 155.75, 135.81, 135.47, 130.33, 130.28, 129.63, 129.56, 129.37, 
129.32, 129.24, 129.16, 128.92, 127.43, 127.31, 125.97, 125.90, 117.27, 114.65, 114.41, 114.31, 
114.26, 114.22, 114.18, 114.15, 114.12, 114.10, 114.05, 113.87, 113.81, 60.99, 60.96, 59.40, 
58.60, 58.10, 55.39, 55.36, 55.27, 53.34, 53.13, 52.87, 52.65, 49.18, 49.14, 48.91, 47.79, 47.51, 
46.77, 46.73, 46.10. 
2.5.11 Peak Assignment for 10g 
 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 390 mg, 84%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.16 – 7.06 (s, 1H), 6.98 – 6.85 (m, 3H), 6.73 – 6.55 (m, 4H), 5.36 (t, 
J = 14.7 Hz, 1H), 5.12 – 5.04 (m, 1H), 4.78 (dd, J = 5.3, 2.1 Hz, 1H), 4.52 – 4.29 (m, 2H), 3.54 
(m, 3H), 3.28 (s, 3H), 3.20 (d, J = 14.4 Hz, 1H), 2.17 (s, 3H). 13C NMR (101 MHz, CDCl3, 
rotamers) δ 167.20, 167.12, 163.85, 162.92, 162.61, 159.61, 156.62, 156.24, 139.53, 139.44, 
135.77, 135.39, 130.30, 130.24, 130.19, 130.03, 130.00, 129.84, 129.48, 129.38, 127.53, 127.39, 
126.50, 122.97, 117.31, 116.98, 114.45, 114.19, 113.92, 113.74, 61.04, 61.00, 59.37, 58.58, 58.12, 








2.5.12 Peak Assignment for 10h 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 404 mg, 87%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 6.98 – 6.77 (m, 6H), 6.73 – 6.57 (m, 2H), 5.36 (dd, J = 14.4, 11.9 Hz, 
1H), 5.12 – 5.06 (m, 1H), 4.78 (dd, J = 8.8, 2.1 Hz, 1H), 4.55 – 4.41 (m, 1H), 4.44 – 4.32 (m, 1H), 
3.50 (s, 3H), 3.28 (s, 3H), 3.18 (dd, J = 14.5, 4.0 Hz, 1H), 2.17 (s, 3H). 13C NMR (101 MHz, 
CDCl3, rotamers) δ 167.22, 167.14, 163.80, 162.91, 162.60, 159.60, 156.68, 156.30, 156.12, 
155.75, 139.24, 139.14, 132.74, 132.35, 130.29, 130.26, 130.24, 130.21, 130.16, 127.51, 127.38, 
125.87, 125.79, 117.29, 116.98, 114.19, 61.03, 61.00, 59.16, 58.36, 58.15, 55.38, 55.32, 53.27, 
53.06, 47.66, 47.42, 46.74, 46.70, 46.11, 21.14. 
2.5.13 Peak Assignment for 10i 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 418 mg, 82%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 6.89 (ddq, J = 8.1, 5.8, 2.8 Hz, 2H), 6.66 (dd, J = 8.4, 5.2 Hz, 3H), 6.49 
(td, J = 8.0, 2.3 Hz, 1H), 6.40 (dd, J = 4.8, 2.2 Hz, 1H), 5.29 (t, J = 14.1 Hz, 1H), 5.07 (d, J = 2.1 
Hz, 1H), 4.72 (dd, J = 7.8, 2.1 Hz, 1H), 4.41 (dd, J = 18.3, 3.6 Hz, 2H), 3.71 – 3.59 (m, 6H), 3.58 
(s, 3H), 3.27 (s, 3H), 3.20 (dd, J = 14.5, 2.4 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 167.13, 
167.08, 163.69, 162.76, 159.59, 156.59, 156.21, 156.03, 155.66, 149.90, 149.85, 149.70, 149.65, 
130.27, 130.20, 128.08, 127.59, 127.47, 127.34, 118.28, 118.23, 117.28, 116.99, 114.14, 111.65, 
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111.57, 108.88, 108.80, 61.00, 60.97, 59.16, 58.38, 58.06, 56.09, 55.97, 55.95, 55.32, 53.25, 53.05, 
47.70, 47.50, 46.65, 46.60, 45.98.  
2.5.14 Peak Assignment for 10j 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (25:75). Yield = 456 mg, 82%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.36 – 7.22 (m, 6H), 6.96 – 6.79 (m, 5H), 6.68 (d, 2H), 5.38 (dd, J = 
14.4, 10.2 Hz, 1H), 5.02 – 4.88 (m, 2H), 4.91 – 4.77 (m, 1H), 4.59 – 4.39 (m, 2H), 3.52 (s, 3H), 
3.31 (s, 3H), 3.22 (dd, J = 14.4, 6.1 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 167.23, 167.17, 
163.74, 162.88, 159.65, 159.44, 159.40, 156.75, 156.38, 155.83, 136.63, 136.59, 132.10, 130.34, 
130.29, 128.83, 128.79, 128.76, 128.71, 128.43, 128.26, 127.92, 127.67, 127.63, 127.61, 127.59, 
127.55, 127.52, 127.43, 127.33, 127.23, 115.92, 115.83, 115.27, 114.32, 114.28, 114.24, 114.19, 
114.17, 114.14, 70.25, 70.23, 58.97, 58.25, 58.17, 55.41, 53.32, 53.10, 47.69, 47.42, 46.13.  
2.5.15 Peak Assignment for 10k 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (25:75). Yield = 400 mg, 79%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 6.89 – 6.80 (m, 4H), 6.72 – 6.61 (m, 4H), 5.86 (ddt, J = 17.3, 10.5, 5.2 
Hz, 1H), 5.33 – 5.04 (m, 4H), 4.77 (dd, J = 9.8, 2.1 Hz, 1H), 4.53 – 4.42 (m, 4H), 3.61 (s, 3H), 
3.28 (s, 3H), 3.20 (dd, J = 14.4, 5.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 167.18, 167.13, 
163.70, 162.84, 159.61, 159.23, 159.17, 156.69, 156.31, 156.15, 155.78, 132.93, 132.88, 130.30, 
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130.25, 127.73, 127.52, 127.39, 127.37, 127.24, 127.14, 118.01, 117.98, 115.71, 115.64, 115.08, 
114.83, 114.45, 114.28, 114.23, 114.19, 114.12, 114.09, 114.07, 68.94, 61.08, 61.05, 58.93, 58.19, 
58.12, 55.36, 55.30, 53.27, 53.05, 47.65, 47.38, 46.74, 46.69, 46.06.  
2.5.16 Peak Assignment for 10l 
 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 335 mg, 75%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 6.66 (dd, J = 8.3, 3.1 Hz, 1H), 6.55 (ddd, J = 8.1, 5.6, 2.2 Hz, 1H), 6.47 
(t, J = 2.6 Hz, 1H), 5.31 (dd, J = 8.3, 2.8 Hz, 1H), 4.19 (s, 1H), 4.17 – 4.06 (m, 2H), 3.69 – 3.63 
(m, 9H), 1.21 (s, 9H). 13C NMR (101 MHz, CDCl3, rotamers) δ 168.04, 167.79, 164.28, 163.32, 
156.31, 155.94, 155.58, 155.22, 149.67, 149.59, 149.24, 149.18, 130.12, 129.60, 118.15, 118.01, 
111.52, 111.44, 108.49, 108.45, 62.68, 62.65, 60.01, 59.64, 59.42, 58.76, 57.85, 56.04, 55.95, 
55.93, 53.70, 53.48, 52.82, 52.60, 48.86, 47.77, 28.00, 27.90.  
2.5.17 Peak Assignment for 10m 
 
Prepared in 5 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 1.895 g, 77%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.30 – 7.21 (m, 5H), 7.02 – 6.92 (m, 2H), 6.87 – 6.78 (m, 2H), 5.36 (d, 
J = 9.6 Hz, 1H), 4.88 (d, J = 4.0 Hz, 2H), 4.26 – 4.10 (m, 3H), 3.70 (s, 3H), 1.25 (s, 9H).
 13C NMR 
(101 MHz, CDCl3) δ 168.03, 167.82, 164.27, 163.35, 159.04, 158.99, 156.40, 156.03, 136.60, 
136.57, 129.97, 128.71, 128.23, 128.22, 127.67, 127.65, 126.95, 126.89, 117.52, 117.28, 117.08, 
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115.69, 115.59, 114.66, 114.42, 114.21, 70.24, 70.22, 62.79, 62.76, 60.14, 59.63, 59.45, 58.60, 
57.67, 53.71, 53.50, 52.86, 52.64, 48.91, 47.82, 28.06, 27.96. 
2.5.18 Peak Assignment for 10n 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (75:25). Yield = 278 mg, 72%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.36 – 7.23 (m, 5H), 5.53 (dd, J = 8.8, 2.8 Hz, 1H), 5.30 (d, J = 2.8 Hz, 
0.5H), 4.82 (d, J = 2.8 Hz, 0.5H), 4.32 – 4.01 (m, 2H), 3.81 (s, 3H), 1.36 (s, 9H). 13C NMR (101 
MHz, CDCl3) δ 167.89, 167.69, 164.26, 163.36, 156.26, 155.89, 155.60, 155.24, 137.83, 137.53, 
129.39, 129.30, 129.02, 128.86, 128.79, 128.71, 128.66, 125.62, 125.58, 117.19, 116.98, 114.33, 
62.64, 62.61, 60.00, 59.64, 59.46, 59.00, 58.08, 53.70, 53.48, 48.09, 48.05, 47.79, 28.00, 27.90. 
2.5.19 Peak Assignment for 10o 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (75:25). Yield = 260 mg, 70%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.31 – 7.09 (m, 5H), 5.20 (dd, J = 13.8, 2.4 Hz, 1H), 4.78 (td, J = 14.3, 
12.4, 6.9 Hz, 1H), 4.46 (d, J = 11.2 Hz, 2H), 4.23 (t, J = 18.5 Hz, 1H), 3.63 (s, 3H), 1.07 (d, J = 
6.9 Hz, 3H), 0.85 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 167.6, 167.4, 163.5, 162.6, 
155.9, 137.9, 137.7, 129.3, 129.2, 128.9, 128.8, 128.6, 128.3, 125.8, 125.6, 125.6, 119.7, 117.2, 
116.9, 114.3, 114.1, 62.1, 62.0, 59.3, 56.9, 56.1, 53.7, 53.5, 47.1, 47.1, 47.0, 46.7, 46.6, 46.1, 19.8, 




2.5.20 Peak Assignment for 10p 
 
Prepared in 1 mmol scale using General Procedure C/D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 299 mg, 79%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.11 (td, J = 4.6, 1.8 Hz, 1H), 6.80 (qd, J = 4.9, 4.2, 2.8 Hz, 2H), 5.29 
(dd, J = 17.0, 2.5 Hz, 1H), 4.54 (dp, J = 28.8, 6.9 Hz, 1H), 4.41 – 4.25 (m, 2H), 4.15 – 4.05 (m, 
1H), 3.66 (d, J = 5.7 Hz, 3H), 3.59 (d, J = 10.5 Hz, 2H), 0.97 (dd, J = 9.0, 6.8 Hz, 3H), 0.82 (dd, 
J = 7.0, 3.3 Hz, 3H). 13C NMR (101 MHz, CDCl3, rotamers) δ 168.13, 168.06, 167.28, 167.08, 
162.95, 162.01, 162.00, 157.66, 157.29, 156.91, 156.54, 156.12, 155.75, 141.92, 141.54, 127.44, 
127.29, 126.27, 126.24, 125.80, 125.68, 120.13, 119.94, 117.48, 117.27, 117.07, 114.63, 114.41, 
114.21, 111.55, 111.35, 62.23, 62.20, 59.33, 53.77, 53.57, 53.29, 52.85, 52.66, 52.63, 46.96, 46.92, 
46.72, 46.64, 19.76, 19.69, 19.59, 19.56. 
2.5.21 Peak Assignment for 11a  
 
Prepared from 1,3-azadiene 9a (936.5 mg, 5.0 mmol) and anhydride 7 (1.056 g, 1.0 equiv) using 
General Procedure C/D. T = 100 oC, time = 8 h. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 1.463 g, 75%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, mixture of rotamers) δ 7.35 – 7.23 (m, 5H), 6.65 – 6.53 (m, 1H), 6.10 (ddd, J = 
15.9, 5.2, 2.8 Hz, 1H), 5.25 (d, J = 2.7 Hz, 1H), 5.15 – 5.05 (m, 1H),  4.35 (q, J = 17.0 Hz, 1H), 
4.18 (d, J = 7.2 Hz, 1H), 3.71 (s, 3H), 1.46 (s, 9H). 13C NMR (101 MHz, CDCl3, rotamers) δ 
165.05, 164.83, 161.03, 160.21, 153.42, 152.37, 132.07, 131.04, 130.53, 125.87, 125.83, 125.71, 
123.68, 122.65, 114.31, 111.45, 56.02, 55.89, 55.39, 53.79, 52.89, 50.58, 50.39, 44.97, 44.93, 
25.08, 24.99.  
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2.5.22 Peak Assignment for 11b 
 
Prepared from 1,3-azadiene 9b (217.3 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using 
General Procedures B. T = 100 oC, time = 8 h. Purification: Flash chromatography on silica eluting 
with hexane/EtOAc (50:50). Yield = 331.5 mg, 71%, 95:5 dr. 1H NMR (400 MHz, Chloroform-d, 
mixture of rotamers) δ 7.25 (d, J = 6.5 Hz, 2H), 6.90 (d, J = 8.5 Hz, 2H), 6.52 (t, J = 15.0 Hz, 1H), 
5.93 (dt, J = 15.9, 6.0 Hz, 1H), 5.22 (d, J = 2.8 Hz, 1H), 5.15 – 5.02 (m, 1H), 4.82 (d, J = 2.8 Hz, 
1H), 4.39 (d, J = 17.0 Hz, 1H), 4.34 – 4.25 (m, 2H), 4.19 (s, 1H), 3.91 – 3.72 (m, 6H), 1.52 (s, 
9H). 13C NMR (101 MHz, CDCl3, rotamers) δ 168.21, 167.99, 164.11, 163.30, 160.20, 160.11, 
152.81, 133.55, 133.00, 130.43, 128.05, 128.02, 123.18, 122.69, 114.32, 114.29, 60.98, 60.95, 
59.04, 58.92, 58.60, 56.93, 56.00, 55.52, 55.41, 53.64, 53.45, 48.84, 48.02, 47.98, 47.84, 28.15, 
28.06.  
2.5.23 Peak Assignment for 11c 
 
Prepared from 1,3-azadiene 9c (1016..5 mg, 5.0 mmol) and anhydride 7 (1055.5 mg, 1.0 equiv) 
using General Procedure C/D. T = 100 oC, time = 8 h. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 1.52 g, 71%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.33 – 7.22 (m, 2H), 6.94 – 6.80 (m, 2H), 6.53 (td, J = 15.8, 1.3 Hz, 
1H), 5.96 (ddd, J = 15.8, 5.9, 1.4 Hz, 1H), 4.83 – 4.68 (m, 2H), 4.43 – 4.20 (m, 2H), 3.92 – 3.73 
(m, 9H), 1.15 (dd, J = 6.8 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 167.86, 167.70, 163.26, 162.50, 
160.20, 160.11, 157.12, 156.74, 133.59, 133.09, 128.04, 128.02, 123.15, 122.80, 114.31, 114.27, 
60.45, 60.42, 57.82, 55.39, 55.38, 55.08, 54.22, 53.61, 53.40, 47.00, 46.95, 46.72, 46.50, 46.12, 
19.98, 19.89, 19.81, 19.79. 
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2.5.24 Peak Assignment for11d 
 
Prepared from 1,3-azadiene 9d (207.3 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using 
General Procedure C/D. T = 100 oC, time = 18 h. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 294 mg, 68%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, mixture of rotamers) δ 7.64 – 7.19 (m, 10H), 6.63 (dd, J = 15.8, 6.6 Hz, 1H), 6.18 
(td, J = 17.2, 16.3, 6.2 Hz, 1H), 5.14 – 4.97 (m, 1H), 4.72 – 4.53 (m, 1H), 4.44 – 4.26 (m, 2H), 
3.70 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 167.80, 167.67, 163.27, 162.51, 157.19, 156.82, 
146.14, 142.83, 140.24, 140.15, 137.95, 137.76, 135.18, 134.58, 129.65, 129.08, 129.06, 129.01, 
128.98, 128.95, 128.91, 128.21, 128.13, 128.09, 126.90, 126.88, 126.20, 126.18, 123.48, 123.14, 
120.04, 119.96, 63.27, 62.45, 57.08, 53.97, 53.77, 47.11, 47.07, 46.70.  
2.5.25 Peak Assignment for 11e 
 
Prepared from 1,3-azadiene 9e (237.3 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using 
General Procedure C/D. T = 100 oC, time = 18 h. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 300 mg, 65%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, mixture of rotamers) δ 7.40 – 7.21 (m, 5H), 7.19 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 
8.6 Hz, 2H), 6.61 (dd, J = 15.8, 7.3 Hz, 1H), 6.15 (ddd, J = 18.1, 15.7, 6.5 Hz, 1H), 5.48 (d, J = 
2.3 Hz, 1H), 5.08 – 4.94 (m, 1H), 4.71 – 4.53 (m, 1H), 4.48 – 4.26 (m, 1H), 3.79 (s, 3H), 3.68 (s, 
3H). 13C NMR (101 MHz, CDCl3) δ 167.84, 167.70, 163.35, 162.60, 159.08, 159.05, 146.31, 
142.74, 135.26, 134.65, 129.10, 129.05, 128.95, 128.93, 128.90, 128.17, 127.59, 127.58, 126.89, 
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126.87, 123.38, 123.03, 121.58, 114.85, 114.83, 114.16, 63.54, 62.70, 59.90, 59.87, 56.96, 55.55, 
53.99, 53.79, 47.06, 47.01. 
2.5.26 Peak Assignment for 11f 
 
Prepared from 1,3-azadiene 9f (221.3 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using 
General Procedure C/D. T = 100 oC, time = 18 h. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 312 mg, 70%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, mixture of rotamers) δ 7.43 – 7.21 (m, 9H), 6.65 (ddd, J = 15.8, 4.0, 1.2 Hz, 1H), 
6.22 (ddd, J = 18.9, 15.8, 6.4 Hz, 1H), 5.08 (ddq, J = 19.2, 4.1, 2.1 Hz, 1H), 4.73 – 4.59 (m, 1H), 
4.45 – 4.20 (m, 1H), 3.87 (s, 3H), 3.81 – 3.65 (m, 1H), 2.33 (s, 3H). 13C NMR (101 MHz, CDCl3) 
δ 167.86, 167.71, 163.30, 162.55, 157.23, 156.85, 138.16, 135.16, 135.06, 134.56, 130.28, 130.26, 
129.04, 128.98, 128.96, 128.91, 126.91, 126.89, 126.04, 123.55, 123.20, 117.45, 117.10, 114.60, 
63.35, 62.52, 57.06, 53.97, 53.76, 47.11, 47.07, 46.72, 21.68, 21.17. 
2.5.27 Peak Assignment for 11g 
 
Prepared from 1,3-azadiene 9g (251 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using 
General Procedure C/D. Purification: Flash chromatography on silica eluting with hexane/EtOAc 
(25:75). Yield = 338.1 mg, 71%, 95:5 dr. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 7.29 – 
7.05 (m, 7H), 6.87 – 6.72 (m, 2H), 6.46 (s, 1H), 4.74 (dt, J = 15.5, 1.7 Hz, 1H), 4.55 – 4.36 (m, 
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2H), 4.22 – 4.12 (m, 1H), 3.74 – 3.60 (m, 6H), 1.77 (s, 3H). 13C NMR (101 MHz, CDCl3) δ 168.26, 
168.15, 168.08, 168.06, 163.86, 163.05, 159.02, 159.01, 157.69, 157.32, 156.94, 156.56, 135.99, 
133.39, 132.49, 129.60, 128.99, 128.89, 128.83, 128.52, 128.48, 127.69, 127.54, 127.36, 127.29, 
120.37, 117.51, 117.47, 114.79, 114.77, 114.68, 114.65, 114.61, 114.54, 68.17, 67.32, 58.17, 
58.14, 55.54, 55.04, 54.03, 53.79, 52.86, 52.64, 49.21, 49.17, 49.14, 49.10, 48.90, 47.01, 46.97, 
46.55, 16.34. 
2.5.28 Peak Assignment for 11h 
 
Prepared from 1,3-azadiene 9h (305.3 mg, 1.0 mmol) and anhydride 7 (211.1 mg, 1.0 equiv) using 
General Procedure C/D. Purification: Flash chromatography on silica eluting with hexane/EtOAc 
(75:25). Yield = 355.2 mg, 67%, 95:5 dr. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 7.38 – 
7.24 (m, 4H), 7.21 – 7.16 (d, J = 8.7, 2H), 6.73 (d, J = 8.7, 2H), 6.41 (dd, J = 15.8, 9.8 Hz, 1H), 
5.87 (td, J = 16.3, 6.3 Hz, 1H), 4.98 – 4.77 (m, 1H), 4.54 – 4.40 (m, 2H), 3.76 (s, 3H), 3.74 – 3.58 
(m, 4H). 13C NMR (101 MHz, CDCl3) δ 167.72, 167.61, 163.35, 162.61, 160.51, 160.41, 157.22, 
156.84, 156.45, 156.08, 140.76, 140.68, 135.07, 134.46, 130.23, 129.80, 128.29, 128.27, 127.42, 
127.33, 124.88, 124.84, 124.80, 123.18, 123.14, 123.10, 123.06, 120.49, 120.15, 114.41, 114.37, 
63.35, 62.54, 60.07, 60.04, 57.17, 55.45, 55.44, 55.40, 54.05, 53.84, 47.10, 47.06, 46.66.  





Prepared from 7c2 (214.2 mg, 0.50 mmol) using General Procedure C. Purification: Flash 
chromatography on silica (pretreated with 1% Et3N) eluting with hexane/EtOAc (80:20). Yield = 
211.3 mg, 89%, 95:5 dr. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 9.81 (s, 1H), 7.30 (d, 
2H), 6.85 (d, 2H), 6.35 (d, J = 15.4 Hz, 1H), 5.97 & 5.84 (dd, J = 15.8, 6.6 Hz, 1H), 4.95 & 4.87 
(ddd, J = 7.0, 2.9, 1.1 Hz, 2H), 4.84 – 4.70 (m, 1H), 3.82 (dd, J = 2.9, 1.1 Hz, 1H), 3.80 – 3.66 (m, 
6H), 1.31 – 1.17 (m, 6H). 13C NMR (101 MHz, CDCl3) δ 185.31, 184.83, 169.39, 167.84, 159.86, 
159.78, 142.36, 141.85, 133.20, 132.05, 128.29, 128.09, 128.07, 124.11, 120.18, 114.11, 114.00, 
104.86, 102.27, 56.93, 56.50, 55.34, 53.19, 53.07, 52.76, 52.59, 47.99, 44.58, 22.26, 21.29, 20.63, 
19.51.  
2.5.30 Peak Assignment for 13 
 
Prepared from 11a (206.2 mg, 0.50 mmol) using General Procedure D. Yield = 201.3 mg, 97%, 
95:5 dr. 1H NMR (400 MHz, Chloroform-d, rotamers) δ 7.22 – 6.95 (m, 5H), 5.18 + 4.74 (dd, J = 
2.9, 1.4 Hz, 1H), 4.18 – 4.02 (m, 3H), 3.63 (s, 3H), 2.58 (ddt, J = 18.7, 8.8, 4.0 Hz, 1H), 2.47 – 
2.32 (m, 1H), 1.88 – 1.62 (m, 2H), 1.19 (s, 9H). 13C NMR (101 MHz, CDCl3) δ 169.09, 168.64, 
163.46, 162.48, 162.47, 157.14, 156.76, 156.31, 155.94, 139.45, 139.26, 129.00, 128.95, 128.35, 
128.33, 126.92, 126.82, 120.35, 117.50, 117.45, 114.64, 114.59, 58.77, 58.61, 57.68, 57.65, 55.28, 
54.42, 53.59, 53.47, 53.38, 47.64, 47.48, 47.44, 36.11, 35.75, 32.29, 32.03, 28.35, 28.22.  
2.5.31 Peak Assignment for 14 
 
To a 10 mL round-bottomed flask equipped with a magnetic stir bar under a N2 atmosphere, in a 
0 °C ice/water bath, was added ester 10m (197 mg, 0.40 mmol) and ethanol (5 mL). NaBH4 (122 
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mg, 3.2 mmol, 8 equiv) was then added portion-wise. The reaction mixture was allowed to warm 
to room temperature overnight (judged complete by GC-MS analysis). After this time, the reaction 
mixture was cooled to 0 °C and diluted with Et2O (10 mL), then quenched by slow addition of a 
solution of 2 N NaOH(aq) (2 mL). The organic layer was washed successively with sat NH4Cl and 
brine, then dried over anhydrous Na2SO4. It was filtered and concentrated in vacuo to yield the 
alcohol as a pale yellow oil. Yield = 136 mg, 92%. 1H NMR (400 MHz, Chloroform-d) δ 7.33 – 
7.15 (m, 5H), 7.03 – 6.94 (m, 2H), 6.94 – 6.81 (m, 2H), 4.92 (s, 2H), 4.60 (d, J = 2.1 Hz, 1H), 3.71 
– 3.46 (m, 3H), 3.36 (s, 2H), 2.83 – 2.71 (m, 1H), 1.26 (q, J = 16.4 Hz, 1H), 1.23 (s, 9H).
 13C NMR 
(101 MHz, CDCl3) δ 169.12, 158.41, 136.81, 134.68, 128.76, 128.22, 127.63, 127.34, 115.38, 
70.25, 60.89, 60.09, 58.91, 58.07, 46.95, 28.33.  
2.5.32 Peak Assignment for 15 
 
To a 10 mL round-bottomed flask equipped with a magnetic stir bar under a N2 atmosphere, at 
room temperature, was added ester 10b (240 mg, 0.50 mmol) dissolved in DCM (5 mL) by means 
of a syringe. Pyrrolidine (71.1 mg, 1.0 mmol, 2 equiv) was then added. The reaction mixture was 
allowed to stir at room temperature until complete conversion (as judged by GC-MS and TLC 
analyses). The mixture was concentrated in vacuo to yield the amino ester as a pale yellow oil. 









CHAPTER 3: EXPLORING THE SCOPE AND MECHANISM OF INTRAMOLECULAR 
HYDROALKYLATION OF IN-SITU GENERATED BIS-HOMOALLYLIC PIPERAZINOLS 
3.1 Introduction  
The 2-oxopiperazine motif constitutes the core of many alkaloid natural products and 
pharmaceuticals that span over thirty therapeutic areas, including antidepressants, antipsychotics, 
anxiolytics, and analgesics.1 Additionally, this privileged scaffold, which ranks among the top 
three N-heterocycles in the U.S. FDA-approved-pharmaceuticals,2 offers an excellent platform 
for systematic scaffolding, given that it may be transformed to other functionalized variants such 
as its saturated piperazine counterpart. Within this peptidomimetic research-suitable platform, is 
a subset of molecules that possess a bicyclic structure formally named 3,9-diazabicyclo[3.3.1] 
nonane (highlighted in Figure 3-1). For example, Ecteinascidin 743 (also known as, Ect-743, 
Trabectedin or Yondelis) is a natural product isolated from the Ecteinascidia turbinate, the sea 
squirt, which demonstrates potent anticancer activity.95 Since 2004, Ect-743 is considered an 
orphan drug in the USA for the treatment of soft-tissue sarcoma and ovarian cancer.96 
Additionally Saframycin A, has potent antiproliferative activity against various tumor cell lines. 
This compound was isolated from Streptomyces lavendulae located in soil, making it a microbial 
based natural product.  
 
Figure 3.1 Examples of bioactive [3.3.1]-azabicyclic piperazines 
57 
 
The prevalence of small molecules as promising drug candidates and common occurrence 
of the [3.3.1] azabicyclic motif in natural products motivate synthetic chemists to find conditions 
for their synthesis and post-modification. This is an example of fragment-based drug discovery 
(FBDD). A major setback of FBDD protocols is its bias towards sp2-enriched compounds by 
incorporation of aromatic rings.97 To side-step this problem, the diversity-oriented synthesis 
(DOS) strategy, which aims to populate new chemical space with drug-like compounds that 
contain a high degree of molecular diversity, has emerged as an essential tool in chemical 
biology and drug discovery.98 DOS is known for generating diverse molecules with both skeletal 
rearrangement and high stereoselectivity. Necessity for chiral, sp3-enriched structures stems from 
nature’s disposition towards these types of compounds and the 3D conformational characteristics 
seen in clinically evaluated compounds.97,99,100 Fittingly, [3.3.1] azabicycles are highly sp3 
enriched. 
The construction of [3.3.1] azabicycles has been demonstrated in the past by cyclization 
of tethers located on the piperazine ring. One of the most known methods is through iminium 
ions which have been long utilized for carbon−carbon and carbon−heteroatom bond formation. 
This tactic is employed in both Pictet-Spengler and Mannich reactions. For example, the 
Hiemstra group synthesized [3.3.1] azabicycles through α-amidoalkylation of N-acyliminium ion 
and π-nucleophiles including aromatic, heteroaromatic, and unsaturated α-H-amino acids 
groups.101 The electrophilic properties of N-acyl iminium ions are due to the electron-
withdrawing nature of the acyl group on nitrogen which makes the iminium carbon more 
electron-deficient. Furthermore, a promising renin inhibitor, named MK-8141, containing the 
bicyclic structure of interest lacked ability for further testing due to limited amounts of product 
available. Recently, scalable diastereoselective intramolecular Dieckmann cyclization of a 
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diester piperazine precursor was employed to forge the [3.3.1] azabicyclic motif resident in MK-
8141.102  
Our attention was brought to this caged scaffold after the opportuned construction of a 
[3.3.1] azabicycle containing a piperazine. In the past, we have reported Grignard addition onto 
our methylated CCR adducts as a form of post-diversification to generate tertiary alcohols.84 
Remarkably, this motif was observed after addition of allyl magnesium bromide onto a CCR 
derived piperazinonate. It is worth noting that the product contains five stereocenters, three of 
which are contiguous and two of which are vicinal. An investigation of the chemoselectivity, 
regioselectivity, and stereoselectivity of in situ-generated bis-homoallylic piperazinol by addition 
of allyl magnesium bromide onto CCR derived lactamoyl esters has been undertaken leading to 
an optimized protocol and increased modularity. Additionally, it was crucial to probe the 
mechanism to fully understand this intriguing transformation. 
3.2 Results and Discussion 
3.2.1 Synthesis of [3.3.1] azabicycles piperazines 
Metallation reactions of enolizable carbonyl-containing compounds with Grignard 
reagents are known to be extremely problematic due to poor chemoselectivity. The most 
common competing processes are nucleophilic addition, reduction and aldol condensation of the 
carbonyl substrate. A potentially beneficial approach is to take advantage of the high 
electrophilicity of a Mg2+ cation and its propensity to form a multicoordinate complex. If 
preformation of a Mg(II) complex with an inherently less reactive carboxylic acid derivative 
such as a lactam is achievable, the acidity of the lactam would be enhanced, thus, allowing for 
enolization by a mild base. Three commonly employed simple basic systems are Mg(OR)2, 
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Mg(OR)X and MgX2/Et3N. To the best of our knowledge, Grignard reagents have proven to be 
incompetent bases for enolization of lactams. 
We commenced studies on the construction of highly functionalized [3.3.1] azabicyclic 
piperazines using model substrate 1g in tetrahydrofuran (THF) with an addition of excess allyl 
magnesium bromide. As seen in Table 3-1, the reaction commenced at –78 oC and was brought 
up to room temperature. At the time of testing conditions, we wanted to develop a protocol that 
would result in high yields of the desired product while diminishing the possibility of 
decomposition. In the first attempts, there was no cyclization prompting us to extend the reaction 
time. At a time of 19 hours we were able to see cyclization. Unfortunately, nucleophilic attack on 
the lactam was observed (see Scheme 3-2, 4a).  
Table 3-1 Optimization of the cyclization of bis-homoallylic alcohols 
 
Although nucleophilic attack was seen, we wanted to ensure that cyclization occurred 
therefore, we continued using these conditions. There was no observed nucleophilic attack on 
sequential reactions which signifies that nucleophilic attack may be substrate dependent. 
Furthermore, a second time optimization and solvent screening was conducted. In this instance, 
we wanted to ensure nucleophilic attack would not occur; therefore, substrate 1l replaced 1g.  
We were able to decrease reaction time by four hours and not compromise the conservation of 
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the tertiary alcohol to a [3.3.1] azabicycle. Additionally, the solvent THF demonstrated to be the 
best for the protocol when compared to Me-THF and THF/TMEDA. 
Table 3-2 Optimization of time and solvent effect for cyclization of bis-homoallylic alcohols 
 
 Following optimization studies, we explored the scope of this cascade process. In this 
event, we find that various electron-rich and electron-neutral aryl-bearing piperazinonates are 
well-tolerated (Scheme 3-1, see 2a–g). Piperazinonates bearing other N-alkyl substituents also 
react prudently with allylmagnesium bromide to afford the bicyclic architectures (see 2h–n). As 
a testament to the generality of the transformation, we have found that allylic piperazinonates 





Scheme 3-1: Hydroalkylation of lactamoyl esters to produce [3.3.1] azabicyles 
Scheme 3-2 shows that not all substrates engaged in cyclization such as 3a-c, which 
formed the bis-homoallylic tertiary alcohol. We have demonstrated that N-alkyl substituted 
allylic piperazinonates are capable of cyclization (see 2o/p). Although speculative, the inability 
of 3d to undergo cyclization suggests that N-aryl substituted piperazinonates are not competent 
substrates for this domino annulation. As stated previously, metallation reactions of enolizable 
carbonyl-containing compounds with Grignard reagents are quite problematic given that 
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nucleophilic addition is often a competing process. As an unfortunate case in point and an 
illustration of the importance of controlling the duration of the reaction, we find that bicycle 2g 
is susceptible to nucleophilic attack after prolonged exposure to afford surprisingly isolable 
tertiary lactamol 4a. These results clearly indicate that these conformationally constrained 
piperazinonates undergo enolization at rates that are much faster than nucleophilic addition.  
 




In an attempt to render the transformation sequential, we subjected bis-homoallylic 
alcohol 3e to a few reaction conditions (Scheme 3-3). However, no cyclization was observed 
with the mass balance being accounted for by recovered starting material or decomposition 
products.  
 
Scheme 3-3: Attempts to induce cyclization of piperazinol 3e 
We know that enolization of the bis-homoallylic piperazinol is possible since we are able 
to intermolecularly trap the corresponding lithium enolate of 3e with methyl iodide (Scheme 3-
4). This result indicates that the transient lithium enolate is incapable of engaging the pendant 
alkenes in a formal hydroalkylation. 
 




In another mechanistically intuitive outcome, these studies have revealed that the use of 
alkenyl Grignard reagents such as vinyl magnesium bromide affords only the bis-allylic tertiary 
piperazinols without cyclization or nucleophilic addition to the lactam (Scheme 3-5). 
 
Scheme 3-5: Chemoselective addition of vinylmagnesium bromide to piperazinonate 1o 
3.2.2 Mechanistic Studies 
We postulate that these [3.3.1] azabicycles are formed through a cascade reaction 
involving the chemoselective addition of allyl magnesium bromide to the piperazinonate 
followed by intramolecular cyclization. In order to fully understand the nuances of the 
transformation, we sought to investigate the potential role of the basic nitrogen (i.e., the methyl-
bearing nitrogen). Specifically, we questioned whether the cyclization proceeds via a 
hydroaminoalkylation or hydroalkylation pathway (Figure 3-4 and Figure 3-5). 
Hydroaminoalkylation 
Figure 3-2 depicts some literature precedence on hydroaminoalkylation of simple olefins 
or styrenes with N-heterocycles.103 Hydroaminoalkylation refers to the addition of a carbon 
adjacent to a nitrogen and a hydrogen across a double bond. In this scheme there are two main 
limitations; (i) a covalently attached directing group such as pyridine is needed on the nitrogen 
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for hydroaminoalkylation to occur and (ii) the diasteroselectivity of the process is low to modest 
with the highest being a dr. of 80:20. Nako and co-workers were able to overcome one of the 
barriers of Chatani’s hydroaminoalkylation by using a scandium TM-catalyst.20 This method of 
hydroaminoalkylation eliminated the prior need of a directing group and it is reagent-controlled. 
 
 
Figure 3-2 Previous hydroaminoalkylation of tertiary amines 
Figure 3-3 displays possible products that could result from hydroaminoalkylation of our 
piperazinonates. There are four possible carbon atoms that can be engaged in a 
hydroaminoalkylation reactions due to them being adjacent to a nitrogen atom. In these 
examples, formation of 5- and 6-membered rings are possible as well as engagement of both allyl 
tethers. The formation of 5- or 6- membered rings is explained by the possibility of linear or 
branch addition of the allyl tether. However, in our case, a single highly caged bridged bicycle is 
formed. The newly formed 6-membered ring was derived from engagement of a single allyl 




Figure 3-3 Examples of possible products through hydroaminoalkylation 
In the event of a hydroaminoalkylation, we surmise that formation of the bis-homoallylic 
alcohol is accompanied by azametallacyclization to form a highly strained metalaziridine 
intermediate as depicted in Figure 3-4. Subsequent 1,2-olefin insertion delivers the branched 
ring-expanded azametallocyclic intermediate, which undergoes reductive elimination to produce 
the [3.3.1] azabicycles.20 Such a mechanism necessitates that the methyl-bearing nitrogen play a 
critical role during the course of the reaction. Furthermore, a transition metal is often employed 
to induce the formation of the metallaaziridine intermediate. However, control experiments have 
revealed that piperidinonates and morpholinates also undergo cascade annulation under similar 
reaction conditions. This work will be revealed in a timely manner. This outcome negates the 
notion that the second nitrogen is necessary for cyclization to occur. These findings and the 
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absence of a transition metal during the course of our reaction strongly point to another pathway 
not involving hydroaminoalkylation. 
 
Figure 3-4 Possible mechanism of hydroaminoalkylation of in situ-generated piperazinols 
Enolate Hydroalkylation of Alkenes 
Enolate hydroalkylation is based on the presence of an enolizable carbonyl compound 
followed by reaction of the transient enolate with the alkene. Hydroalkylation of aryl-conjugated 
olefins with potassium enolates derived from N-methyl-2-pyrrolidinone and N-methyl-2-
piperidone have been reported.104 Gleaning from this precedence, we postulate that 
hydroalkylation of piperazinonates starts by the chemoselective addition of allylmagnesium 
bromide to the ester motif to afford the corresponding bis-homoallylic alkoxide (Figure 3-5). At 




Figure 3-5 Possible mechanism of hydroalkylation 
In this scenario, the Grignard reagent might be serving as both a nucleophile and a base. 
To the best of our knowledge, Grignard reagents have proven to be incompetent bases for 
enolization of lactams. A potentially beneficial approach is to take advantage of the high 
electrophilicity of an Mg2+ cation and its propensity to form a multicoordinate complex. If 
preformation of a Mg(II) complex with an inherently less reactive carboxylic acid derivative 
such as a lactam is achievable, the acidity of the lactam would be enhanced, thus, allowing for 
enolization by a mild base. Three commonly employed simple basic systems are Mg(OR)2, 
Mg(OR)X and MgX2/Et3N.
105 (Figure 3-6). A close inspection of bis-homoallylic intermediate 




Figure 3-6 Evidence of enolate hydroalkylation of alkenes and formation of a magnesium 
enolate from a lactam 
 
At this point, we propose that the all-important magnesium enolate is formed by 
intramolecular enolization using the transiently generated magnesium alkoxide. An updated 
mechanism is shown in Figure 3-7. 
 
Figure 3-7 Updated mechanism of Hydroalkylation 
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3.3 Conclusions: In summary, the scope and mechanism of a stereoselective-, branched-
regioselective-, and operationally simple approach to highly functionalized piperazines 
containing [3.3.1]-azabicycles has been explored. The modularity of the starting material was 
expanded leading to a diverse set of [3.3.1]-azabicycles. Mechanistic studies point to an 
intramolecular hydroalkylation process, predicated on the enolization of a relatively unreactive 
lactam unit by an in situ generated magnesium alkoxide. The [3.3.1] azabicyclic piperazinols are 
currently undergoing structure-activity-relationship (SAR) studies on neglected tropical diseases 
(NTDs), including leishmaniasis. 
3.4 General Procedures 
 All experiments involving air and moisture sensitive reagents were carried out under an 
inert atmosphere of nitrogen and using freshly distilled solvents. Column chromatography was 
performed on silica gel (230-400 mesh). Thin-layer chromatography (TLC) was performed using 
Silicycle SiliaplateTM glass backed plates (250 µm thickness, 60 Å porosity, F-254 indicator) 
and visualized using UV (254 nm) or KMnO4 stain. Unless otherwise indicated, 
1H, 13C, DEPT-
135 NMR, COSY 45, and NOESY spectra were acquired using CDCl3 as solvent at room 
temperature. Chemical shifts are quoted in parts per million (ppm). HRMS-EI+ data were 
obtained using either electronspray ionization (ESI) or electron impact (EI) techniques.  
3.4.1 General Procedure A: Reaction of aryl imines with N-methyl morpholine 2,6-dione 
A 5 mL screw-cap vial was flame-dried, evacuated and flushed with nitrogen. A solution 
of the imine (1.0 mL, 0.10 M in freshly distilled toluene) was added to the vial at room 
temperature followed by anhydride (1 equiv). The contents were placed in a pre-heated oil bath 
thermostatted 100 oC. After complete consumption of the imine (as judged by TLC and NMR), 
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the mixture/suspension was cooled to room temperature and washed several times with 
petroleum ether, then concentrated under reduced pressure to afford the crude cycloadducts. 
3.4.2 General Procedure B: Methyl esterification of cycloadducts 
To a stirring suspension of the acid (1 mmol), dissolved in DMF (5 mL), and K2CO3 (3 
equiv) methyl iodide (2 equiv) was added under nitrogen atmosphere. The reaction mixture was 
stirred for about 12 h (TLC monitoring). After complete conversion, it was diluted with water 
and extracted with EtOAc (2×20 mL). The combined organic extracts were washed with brine, 
dried over MgSO4 and concentrated in vacuo to give the desired ester, which was purified by 
flash chromatography on silica. 
3.4.3 General Procedure C: Grignard Addition on methylated cycloadducts 
To the crude lactamoyl ester (1.0 mmol) dissolved in freshly distilled THF (5 mL), was 
slowly added allyl magnesium bromide (2.0 mL, 1.0 M solution in THF, 3 equiv) under nitrogen 
at ‒78 °C. The reaction was kept at –78 °C for 30 minutes and slowly brought up to room 
temperature. The reaction remained in room temperature for 14 -15 hours. The mixture was 
quenched with sat. aq NH4Cl and diluted with EtOAc. The layers were separated and the 
aqueous layer was extracted twice with EtOAc. The combined organic layers were dried over 
MgSO4 for 20 min, filtered, and concentrated under reduced pressure to give the desired product. 
Purification: Flash chromatography on silica eluting with Hexane/EtOAc (75:25, 50:50 and 
0:100). 
 3.4.4 General Procedure D: Lithium enolate- electrophile trapping 
 To a tertiary alcohol (1.0 mmol) dissolved in freshly distilled THF (5 mL), was slowly 
added tert-butyl lithium (2.0 mL, 1.0 M solution in THF, 3 equiv) under nitrogen at ‒78 °C. The 
reaction was kept at –78 °C for 30 minutes. The electrophile was added after the 30 minutes. The 
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mixture was quenched with sat. aq NH4Cl at ‒78 °C and diluted with EtOAc. The layers were 
separated and the aqueous layer was extracted twice with EtOAc. The combined organic layers 
were dried over MgSO4 for 20 min, filtered, and concentrated under reduced pressure to give the 
desired product. Purification (if needed): Flash chromatography on silica eluting with 





















3.4 Peak Assignments 
3.4.1 Peak Assignment for 2a 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 285 mg, 83%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.32 – 7.23 (m, 5H), 6.01 (tt, J = 17.0, 7.4 Hz, 1H), 5.27 – 5.18 (m, 
2H), 4.35 (s, 1H), 3.78 (s, 1H), 3.39 (h, J = 6.7 Hz, 1H), 3.11 (d, J = 4.6 Hz, 1H), 2.75 (s, 1H), 
2.54– 2.41 (m, 4H), 2.30 (dt, J = 13.4, 6.4 Hz, 1H), 1.67 (dd, J = 14.2, 4.3 Hz, 1H), 1.42 (d, J = 
6.8 Hz, 3H), 1.30 – 1.15 (m, 4H), 1.00 (d, J = 6.9 Hz, 3H). 13C NMR (101 MHz, CDCl3) δ 169.35, 
142.97, 132.96, 128.55, 127.41, 127.32, 118.85, 72.32, 68.70, 65.52, 60.42, 52.62, 44.31, 43.46, 
38.61, 29.65, 21.29, 19.37, 18.20. 
3.4.2 Peak Assignment for 2b 
 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 314 mg, 80%, 95:5 dr.  




Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 303 mg, 85%, 95:5 dr. 
1
H NMR (400 MHz, 
Chloroform-d-rotamers) δ 7.30 – 7.23 (m, 2H), 7.16 (d, J = 7.5 Hz, 2H), 6.04 (ddt, J = 17.3, 10.3, 
7.0 Hz, 1H), 5.31 – 5.21 (m, 2H), 4.36 (s, 1H), 3.84 (s, 1H), 3.40 (hept, J = 6.7 Hz, 1H), 3.13 (d, 
J = 4.7 Hz, 1H), 2.78 (q, J = 1.3 Hz, 1H), 2.59 (s, 3H), 2.58 – 2.44 (m, 2H), 2.36 – 2.26 (m, 4H), 
1.74 – 1.65 (m, 1H), 1.47 (d, J = 6.8 Hz, 3H), 1.33 – 1.16 (m, 4H), 1.04 (d, J = 7.0 Hz, 3H). 
13
C 
NMR (101 MHz, CDCl
3
) δ 169.36, 139.94, 137.11, 132.99, 129.25, 127.25, 118.77, 72.25, 68.89, 
65.58, 60.30, 52.74, 44.43, 43.28, 38.50, 30.05, 21.31, 21.08, 19.32, 18.19. 
 
3.4.4 Peak Assignment for 2d 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 281 mg, 79%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.37 (s, 1H), 7.24 – 7.18 (dd, J = 6.6, 1.6 Hz, 2H), 7.11 – 7.04 (m, 1H), 
6.05 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 5.33 – 5.20 (m, 2H), 4.35 (s, 1H), 3.88 – 3.84 (m, 1H), 3.39 
(hept, J = 6.7 Hz, 1H), 3.16 – 3.10 (m, 1H), 2.84 – 2.74 (m, 1H), 2.59– 2.45 (m, 5H), 2.43 – 2.26 
(m, 5H), 1.74 – 1.65 (m, 1H), 1.48 (d, J = 6.7 Hz, 3H), 1.34 – 1.11 (m, 4H), 1.04 (d, J = 7.0 Hz, 
3H). 13C NMR (101 MHz, CDCl3) δ 169.43, 142.90, 138.25, 133.05, 128.43, 128.12, 124.35, 
118.73, 72.27, 68.78, 65.56, 60.52, 52.90, 44.42, 43.26, 38.50, 30.11, 21.53, 21.32, 19.31, 18.19. 




Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 301 mg, 72%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.68 – 7.56 (m, 4H), 7.47 (dq, J = 7.8, 4.7, 2.8 Hz, 4H), 7.41 – 7.31 (m, 
1H), 6.08 (ddt, J = 17.2, 10.2, 7.0 Hz, 1H), 5.35 – 5.25 (m, 2H), 4.44 (s, 1H), 3.79 (s, 1H), 3.49 
(dt, J = 13.5, 6.7 Hz, 1H), 3.18 (d, J = 4.6 Hz, 1H), 2.84 (s, 1H), 2.66 – 2.36 (m, 6H), 1.72 (dd, J = 





) δ 169.34, 142.04, 140.37, 140.27, 133.00, 128.91, 127.79, 127.54, 127.22, 
127.04, 118.90, 72.37, 68.76, 65.58, 60.24, 52.71, 44.38, 43.50, 38.70, 29.70, 21.36, 19.44, 18.21. 
3.4.6 Peak Assignment for 2f 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 324 mg, 87%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ  7.34 – 7.25 (m, 2H), 6.92 – 6.81 (m, 2H), 6.10 – 5.96 (m, 1H), 5.33 – 
5.25 (m, 2H), 4.34 (s, 1H), 3.82 (s, 3H), 3.45 (m, J = 6.9 Hz, 1H), 3.15 (d, J = 4.7 Hz, 1H), 2.76 
(s, 1H), 2.60 – 2.40 (m, 5H), 2.40 – 2.28 (m, 1H), 1.73 – 1.03 (m, 13H). 
13
C NMR (101 MHz, 
CDCl
3
) δ 169.32, 158.78, 134.80, 132.94, 128.48, 118.85, 113.86, 72.30, 68.82, 65.53, 59.89, 




3.4.7 Peak Assignment for 2g 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 358 mg, 89%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 6.95 – 6.86 (m, 2H), 6.84 (d, J = 8.3 Hz, 1H), 6.06 (ddt, J = 17.1, 10.2, 
7.0 Hz, 1H), 5.34 – 5.22 (m, 2H), 4.32 (s, 1H), 3.89 – 3.79 (m, J = 11.1 Hz, 6H), 3.42 (hept, J = 
6.8 Hz, 1H), 3.14 (d, J = 4.7 Hz, 1H), 2.80 (d, J = 1.6 Hz, 1H), 2.62– 2.44 (m, 5H), 2.40 – 2.28 
(m, 1H), 1.73 – 1.59 (m, 1H), 1.49 (d, J = 6.7 Hz, 3H), 1.35 – 1.17 (m, 5H), 1.04 (d, J = 7.0 Hz, 
3H). 
13
C NMR (101 MHz, CDCl
3
) δ 169.34, 148.90, 148.17, 135.36, 133.16, 119.61, 118.66, 
110.88, 110.42, 72.26, 68.67, 65.54, 60.16, 55.97, 52.78, 44.50, 43.23, 38.79, 29.96, 21.46, 19.35, 
18.18. 
 
3.4.8 Peak Assignment for 2h 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 313 mg, 88%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.34 – 7.17(d, J = 7.7 m, 5H), 6.18 – 6.02 (m, 1H), 5.35 – 5.24 (m, 
2H), 4.75 (br. s, 1H), 3.42 (s, 1H), 3.13 (d, J = 4.3 Hz, 1H), 2.71 (s, 1H), 2.49 – 2.29 (m, J = 14.2, 
6.9 Hz, 6H), 1.66 (dd, J = 14.0, 4.4 Hz, 1H), 1.56 – 1.43 (m, 1H), 1.37 (s, 9H), 0.98 (d, J = 6.9 Hz, 
3H). 
13
C NMR (101 MHz, CDCl
3
) δ 169.54, 144.67, 133.18,, 128.01, 127.46, 127.10, 118.72, 
72.56, 71.71, 69.17, 67.06, 60.45, 59.33, 58.29, 56.91, 47.59, 44.42, 44.05, 41.55, 41.22, 40.01, 




3.4.9 Peak Assignment for 2i 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 347 mg, 90%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ δ 7.24 (s, 2H), 6.91 – 6.78 (m, 2H), 6.08 (dt, J = 16.7, 9.0 Hz, 1H), 
5.34 –5.12 (m, 3H), 4.71 (s, 1H), 3.79 (s, 3H), 3.12 (d, J = 4.2 Hz, 1H), 2.68 (s, 1H), 2.49 – 2.37 
(m, 6H), 1.65 (dd, J = 14.2, 4.4 Hz, 1H), 1.55 – 1.42 (m, 1H), 1.38 (s, 9H), 0.98 (d, J = 6.9 Hz, 
3H). 
13
C NMR (101 MHz, CDCl
3
) δ 169.54, 158.58, 136.55, 133.24, 128.55, 118.91, 113.32, 
72.51, 69.27, 67.09, 59.25, 57.67, 55.29, 44.35, 44.15, 40.04, 29.23, 28.84, 18.23. 
 
3.4.10 Peak Assignment for 2j 
 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 358 mg, 86%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 6.89 – 6.81 (m, 2H), 6.75 (d, J = 8.3 Hz, 1H), 6.18 – 6.03 (m, 1H), 5.31 
– 5.21 (m, 2H), 4.67 (s, 1H), 3.82 (d, J = 9.9 Hz, 6H), 3.49 (s, 1H), 3.09 (d, J = 4.2 Hz, 1H), 2.71 
(d, J = 1.7 Hz, 1H), 2.50 – 2.35 (m, 5H), 2.30 (ddt, J = 17.0, 8.6, 3.5 Hz, 1H), 1.62 (dd, J = 13.9, 
4.4 Hz, 1H), 1.52 –1.37 (m, 10H), 0.95 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl
3
) δ 169.53, 
148.50, 147.96, 137.22, 133.66, 119.71, 118.45, 110.78, 110.55, 72.47, 69.13, 67.09, 59.34, 57.78, 




3.4.11 Peak Assignment for 2k 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on 
silica eluting with hexane/EtOAc (50:50). Yield = 269 mg, 73%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.30 – 7.21 (m, 5H), 6.05 (dq, J = 16.1, 7.5 Hz, 1H), 5.28 – 5.19 (m, 
2H), 4.45 (s, 1H), 3.89 (s, 1H), 3.63 – 3.44 (m, 1H), 3.07 (d, J = 5.1 Hz, 1H), 2.82 – 2.42 (m, 
5H), 2.27 (dq, J = 13.1, 6.8, 6.2 Hz, 1H), 2.20 – 2.08 (m, 1H), 1.78 – 1.65 (m, 7H), 1.44 (tt, J = 
16.0, 6.8 Hz, 1H), 1.36 – 1.12 (m, 2H), 0.97 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl
3
) δ 
169.03, 143.33, 133.18, 128.47, 127.21, 127.11, 118.64, 72.15, 68.99, 65.63, 61.88, 60.70, 44.39, 
43.32, 38.72, 30.36, 29.82, 29.04, 24.67, 23.99, 18.22. 
3.4.12 Peak Assignment for 2l 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 290 mg, 76%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.22 (d, J = 7.9 Hz, 2H), 7.22 – 7.10 (m, 2H), 6.08 (ddt, J = 18.3, 9.4, 
7.0 Hz, 1H), 5.31 – 5.22 (m, 2H), 4.45 (s, 1H), 4.01 – 3.82 (br. s, 1H), 3.57 (p, J = 8.3 Hz, 1H), 
3.10 (d, J = 4.6 Hz, 1H), 2.84 (s, 1H), 2.53 – 2.47 (m, 5H), 2.30 – 2.20 (m, 6H), 1.83 – 1.66 (m, 
7H), 1.52 –1.16 (m, 4H), 1.01 (d, J = 7.0 Hz, 3H). 
13
C NMR (101 MHz, CDCl
3
) δ 168.96, 140.30, 
136.84, 133.22, 129.15, 127.03, 118.56, 72.09, 69.09, 65.66, 61.94, 60.57, 44.47, 43.23, 38.65, 




3.4.13 Peak Assignment for 2m 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 306 mg, 69%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.61 (ddd, J = 11.1, 7.8, 1.8 Hz, 4H), 7.50 – 7.33 (m, 5H), 6.21 – 6.06 
(m, 1H), 5.36 – 5.27 (m, 2H), 4.55 (s, 1H), 4.00 (s, 1H), 3.65 (p, J = 8.3 Hz, 1H), 3.15 (d, J = 4.6 
Hz, 1H), 2.93 (s, 1H), 2.59 – 2.52 (m, 5H), 2.40 – 2.20 (m, 2H), 1.96 –1.52 (m, 6H), 1.44 – 1.22 
(m, 1H), 1.05 (d, J = 7.0 Hz, 3H), 0.95 (s, 3H). 
13
C NMR (101 MHz, CDCl
3
) δ 169.01, 142.43, 
140.34, 140.07, 133.23, 128.90, 127.59, 127.53, 127.13, 127.02, 118.70, 76.79, 72.16, 69.08, 
65.70, 62.06, 60.56, 44.56, 43.28, 38.72, 30.62, 29.90, 29.13, 24.75, 24.06, 18.26. 
3.4.14 Peak Assignment for 2n 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 302 mg, 71%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.35 – 7.25 (m, 2H), 6.93 – 6.80 (m, 2H), 6.03 (ddt, J = 17.2, 10.2, 7.0 
Hz, 1H), 5.31 – 5.19 (m, 2H), 4.33 (s, 1H), 3.88 – 3.76 (m, 5H), 3.12 (d, J = 4.8 Hz, 2H), 2.88 – 
2.79 (m, 3H), 2.59 (s, 3H), 2.54 – 2.48 (m, 1H), 2.50 – 2.39 (m, 1H), 2.42 – 2.25 (m, 1H), 2.16 
(qd, J = 12.1, 10.4, 4.5 Hz, 1H), 1.92 (ddt, J = 14.3, 7.2, 3.5 Hz, 1H), 1.79 – 1.62 (m, 5H), 1.54 – 
1.30 (m, 2H), 1.27 (s, 1H), 1.25 – 1.09 (m, 1H), 1.13 – 1.00 (m, 3H). 
13





δ 168.78, 158.68, 134.79, 133.01, 128.43, 118.70, 113.97, 72.18, 68.90, 65.43, 63.60, 60.88, 55.34, 
44.42, 43.10, 38.33, 33.97, 30.87, 30.22, 28.81, 26.99, 26.40, 26.36, 18.23. 
3.4.15 Peak Assignment for 2o 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (50:50). Yield = 287 mg, 75%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.44 – 7.20 (m, 5H), 6.50 – 6.35 (m, 2H), 6.11 (dddd, J = 16.9, 10.5, 
8.7, 5.5 Hz, 1H), 5.34 – 5.25 (m, 2H), 4.47 (dd, J = 4.8, 2.2 Hz, 1H), 3.10 – 2.76 (m, 2H), 2.69 – 
2.58 (m, 5H), 2.37– 2.20 (m, 2H), 1.70 – 1.60 (m, 1H), 1.52 – 1.36 (m, 10H), 0.94 (d, J = 7.0 Hz, 
3H).
 13
C NMR (101 MHz, CDCl
3
) δ 168.78, 136.38, 134.92, 133.58, 129.38, 128.85, 127.97, 
126.21, 118.25, 72.26, 69.75, 67.55, 58.66, 56.68, 45.47, 43.41, 39.45, 31.04, 29.00, 17.98. 
 
3.4.16 Peak Assignment for 2p 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (25:75). Yield = 325 mg, 79%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.38 – 7.22 (m, 2H), 6.96 – 6.83 (m, 2H), 6.36 – 6.10 (m, 3H), 5.35 – 
5.21 (m, 2H), 4.44 (d, J = 7.6 Hz, 1H), 4.07 (s, 1H), 3.83 (s, 3H), 3.09 – 2.95 (m, 1H), 2.72 – 2.57 
(m, 5H), 2.42 – 2.19 (m, 3H), 1.65 – 1.15 (m, 10H), 0.94 (d, J = 6.9 Hz, 3H). 
13
C NMR (101 MHz, 
CDCl
3
) δ 168.76, 159.51, 133.57, 132.72, 129.13, 128.79, 127.36, 118.20, 114.26, 72.23, 69.78, 




3.4.17 Peak Assignment for 5 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (0:100). Yield = 364 mg, 92%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.34 – 7.26 (m, 6H), 6.42 – 6.30 (m, 2H), 5.90 (dddd, J = 27.8, 17.2, 
13.2, 7.3 Hz, 2H), 5.18 (dq, J = 17.1, 8.9 Hz, 4H), 4.59 (d, J = 6.6 Hz, 1H), 3.71 (q, J = 6.8 Hz, 
1H), 2.99 – 2.94 (m, 1H), 2.63 (s, 3H), 2.40 (d, J = 7.2 Hz, 4H), 1.51 (s, 9H), 1.43 (m, 3H). 
13
C 
NMR (101 MHz, CDCl
3
) δ 172.24, 136.75, 134.22, 133.55, 133.41, 130.11, 128.73, 127.73, 
126.38, 119.46, 119.38, 78.27, 77.42, 77.10, 68.17, 60.22, 58.43, 55.65, 43.14, 42.56, 41.29, 28.56, 
18.90. 
 
3.4.18 Peak Assignment for 6 
 
Prepared in 1 mmol scale using General Procedure D. Purification: Flash chromatography on silica 
eluting with hexane/EtOAc (0:100). Yield = 301 mg, 85%, 95:5 dr. 1H NMR (400 MHz, 
Chloroform-d, rotamers) δ 7.42 - 7.28 (m, 5H), 6.42 (d, J = 16.0 Hz, 1H), 6.18 – 6.04 (m, 3H), 
5.48 (d, J = 17.2 Hz, 1H), 5.37 (d, J = 17.2 Hz, 1H), 5.27 (d, J = 10.8 Hz, 1H), 5.18 (d, J = 10.6 
Hz, 1H), 4.74 (d, J = 6.6 Hz, 1H), 3.44 – 3.33 (m, 2H), 3.02 (s, 1H), 2.83 (s, 1H), 2.49 (s, 3H), 
1.45 (s, 9H). 
13
C NMR (101 MHz, CDCl
3
) δ 169.14, 141.88, 139.72, 136.24, 132.01, 130.56, 
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APPENDIX A: CHAPTER 2 SPECTROSCOPIC DATA 
 





Spectra 1-2 Carbon NMR spectrum of 8a. 
 




Spectra 1-4 Proton NMR spectrum of 8b. 
 




Spectra 1-6 DEPT-135 NMR spectrum of 8b. 
 




Spectra 1-8 Carbon NMR spectrum of 8c. 
 




Spectra 1-10 Proton NMR spectrum of 8d. 
 


















Spectra 1-14 Proton NMR spectrum of 10a. 
 





















Spectra 1-19 Proton NMR spectrum of 10b. 
 





















Spectra 1-24 Proton NMR spectrum of 10c. 
 




Spectra 1-26 DEPT-135 NMR spectrum of 10c. 
 




Spectra 1-28 Carbon NMR spectrum of 10d. 
 




Spectra 1-30 Proton NMR spectrum of 10e. 
 





















Spectra 1-35 Proton NMR spectrum of 10f. 
 















Spectra 1-39 Proton NMR spectrum of 10g. 
 




Spectra 1-41 DEPT-135 NMR spectrum of 10g. 
 




Spectra 1-43 Carbon NMR spectrum of 10h. 
 











Spectra 1-46 Proton NMR spectrum of 10i. 
 




Spectra 1-48 DEPT-135 NMR spectrum of 10i. 
 




Spectra 1-50 Carbon NMR spectrum of 10j. 
 




Spectra 1-52 Proton NMR spectrum of 10k. 
 





















Spectra 1-57 Proton NMR spectrum of 10l. 
 


















Spectra 1-61 Proton NMR spectrum of 10m. 
 
Spectra 1-62 Carbon NMR spectrum of 10m. 
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Spectra 1-63 DEPT-135 NMR spectrum of 10m. 
 




Spectra 1-65 Carbon NMR spectrum of 10n. 
 




Spectra 1-67 Proton NMR spectrum of 10o. 
 




















Spectra 1-72 Proton NMR spectrum of 10p. 
 



















Spectra 1-77 Proton NMR spectrum of 11a. 
 













Spectra 1-81 Proton NMR spectrum of 11b. 
 




Spectra 1-83 DEPT-135 NMR spectrum of 11b. 
 




Spectra 1-85 Carbon NMR spectrum of 11c. 
 










Spectra 1-88 Proton NMR spectrum of 11d. 
 














Spectra 1-92 Proton NMR spectrum of 11e. 
 




Spectra 1-94 DEPT-135 NMR spectrum of 11e. 
 




Spectra 1-96 Carbon NMR spectrum of 11f. 
 
















Spectra 1-100 Proton NMR spectrum of 11g. 
 



















Spectra 1-105 Proton NMR spectrum of 11h. 
 




Spectra 1-107 DEPT-135 NMR spectrum of 11h. 
 




Spectra 1-109 Carbon NMR spectrum of 12. 
 

















Spectra 1-113 Proton NMR spectrum of 13. 
 


















Spectra 1-117 Proton NMR spectrum of 14. 
 





Spectra 1-119 DEPT-135 NMR spectrum of 14. 
 




Spectra 1-121 Carbon NMR spectrum of 15. 
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Spectra 2-2 Carbon NMR spectrum of 2a. 
 





Spectra 2-4 Proton NMR spectrum of 2b. 
 















Spectra 2-8 Proton NMR spectrum of 2c. 
 















Spectra 2-12 Proton NMR spectrum of 2d. 
 
 





Spectra 2-14 DEPT-135 NMR spectrum of 2d. 
 
 





Spectra 2-16 Carbon NMR spectrum of 2e. 
 




Spectra 2-18 Proton NMR spectrum of 2f. 
 















Spectra 2-22 Proton NMR spectrum of 2g. 
 
















Spectra 2-26 Proton NMR spectrum of 2h. 
 
 









Spectra 1-29 DEPT-135 NMR spectrum of 2i. 
 




Spectra 2-31 Carbon NMR spectrum of 2i. 
 




Spectra 2-33 Proton NMR spectrum of 2j. 
 




Spectra 2-35 DEPT-135 NMR spectrum of 2j. 
 




Spectra 2-37 Carbon NMR spectrum of 2k. 
 










Spectra 2-40 Proton NMR spectrum of 2l. 
 














Spectra 2-44 Proton NMR spectrum of 2m. 
 
















Spectra 2-48 Proton NMR spectrum of 2n. 
 
















Spectra 2-52 Proton NMR spectrum of 2o. 
 















Spectra 2-56 Proton NMR spectrum of 2p. 
 




Spectra 2-58 DEPT-135 NMR spectrum of 2p. 
 




Spectra 2-60 Carbon NMR spectrum of 9. 
 




Spectra 2-62 Proton NMR spectrum of 6. 
 





Spectra 2-64 DEPT-135 NMR spectrum of 6. 
 
 
 
 
 
 
 
 
 
 
 
